



DEPARTMENT OF CHEMISTRY 
 
D’CUNHA, NAPOLEON      B.S. UNIVERSITY OF TORONTO, 2009  
  
PIONEERING A NOVEL CLASS OF TETRAHYDROIMIDAZOPYRIDINES WITH 
ANTI-PROLIFERATIVE PROPERTY STUDY AGAINST PROSTATE CANCER 
 
Committee Chair: Xiu-Ren Bu, Ph.D. 
Dissertation dated May 2016  
The synthesis of tetrahydroimidazo[1,5-a]pyridine (rIMP) through the transfer 
hydrogenation of imidazo[1,5-a]pyridine (IMP) was successfully developed. The simple 
two-step procedure is the most viable and efficient method that results in a uniquely 
conjugated system with pyridine at the 1-position and functionalized phenyl group at the 
3-position.  
In the synthesis of imidazo[1,5-a]pyridine, the reaction between di-2-pyridil 
ketone, substituted benzaldehyde and ammonium acetate in acetic acid under N2 was 
highly successful, resulting in yields ranging from 35-95%. Highest yields were obtained 
for compounds that had electron withdrawing groups on them. 
The transfer hydrogenation of IMP using recyclable and commonly used Pd/C 
catalyst, hydrazine hydrate in ethanol under N2 was shown to be viable and efficient in 
the synthesis of rIMP. The reaction conditions for the nitro based IMP were optimized to 
ii 
 
give singly- or doubly- reduced products, amine-IMP or amine-rIMP, respectively. The 
optimization of reaction conditions in the synthesis of amine-IMP led to the discovery of 
1: 3 mol%: 3 eq ratio of IMP, Pd/C, and hydrazine hydrate to obtain high yields. An 
optimal temperature of 90 oC and a reaction duration of 1.5 hr were established. The 
optimization of reaction condition for the synthesis of amine-rIMP revealed that 1: 15 
mol%: 15 eq ratio of IMP, Pd/C, and hydrazine hydrate lead to high yield. The presence 
of hydroxy, alkyl and methoxy group was unaffected. The optimized condition for 
synthesis of amine-rIMP was used on other functionalized IMP. Hydrogenolysis was 
observed for halogenated (bromine- and chlorine-) IMP to give non-functionalized rIMP. 
The fluorine atom was not affected by the condition and resulted in fluorine-rIMP. The 
nitrile group was reduced completely to methyl. The ethoxy and acetamide groups were 
unaffected. The thiomethyl group was poisonous to the catalyst.  
Anti-proliferative assay on human prostate cancer cell lines, PC3 and DU145 
revealed that rIMP is more potent at inhibiting growth of PC3 cells and IMP more potent 
at inhibiting growth of DU145 cells. Of the various treatments amine-rIMP were more 
potent at inhibiting PC3 cells than Me-rIMP, amine-IMP and OH-IMP. Amine at the 
ortho-position was most potent compared to meta- and para-position. Cell growth of PC3 
cells was inhibited in a dose-dependent manner.
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BACKGROUND AND LITERATURE REVIEW 
1.1 Imidazole and Its Derivatives 
Imidazole containing molecules are important in biology, chemistry, 
pharmaceutical, veterinary, and agrochemical products (1-4). Their wide arrays of 
activities are due to its five-membered heterocyclic aromatic core ring system. The 
structural motif of imidazole is present in some well-known components of important 
human compounds (Figure 1), i.e., the amino acid histidine, the purines bases of DNA, 
histamine and biotin, thus participating in many significant biological activities (5). The 
development and application of imidazole derivatives may therefore be of great 
medicinal interest.  
 




Properties of the five–membered imidazole ring system result from the presence 
of both pyrrole and pyridine nitrogen atoms linked in a conjugated system (Figure 2). 
The carbons and pyridine nitrogen (N3) all contribute one electron, while the pyrrole 
nitrogen (N1) contributes its lone pair (two electrons) to give six π-electrons (Figure 2b). 
As a result of the imidazole moiety having alternate double bond, being co-planar and 
satisfying the Huckle rule of 4n+2 electron systems, is aromatic, resulting in higher 
stability. Of the wide array of molecules that have the imidazole moiety, 
tetrahydroimidazo[1,5-a]pyridine (THIP) and imidazo[1,5-a]pyridine (IMP) will be 
discussed in details in the following sections.   
 
Figure 2. Structural orientation of Imidazole (a) and its π-conjugation system (b). 
 
1.2 Tetrahydroimidazopyridine (THIP) 
Tetrahydroimidazopyridine (THIP) belongs to a class of imidazoles that are used 
in a wide array of medicinal and biological fields. They have been used as anti-cancer (6-




bacterial agents (13).  Medicinal and biological properties of THIP stem from the 
presence of imidazole moiety to mimic imidazole in enzymes and biological pathways 
thus possessing agonistic/antagonistic capabilities.  
THIP consists of a five-membered aromatic imidazole ring fused to a six-
membered piperidine ring (Figure 3). Of the different structural isomers that are present, 
the isomers 5,6,7,8-tetrahydroimidazo[1,5-a]pyridine (1), 5,6,7,8-tetrahydroimidazo[1,2-
a]pyridine (2) and 4,5,6,7-tetrahydro-3H-imidazo[4,5-c]pyridine (3) are the most 
common and widely used (Figure 3). Compounds 1 and 2 are similar to each other, in that 
the pyrrole nitrogen is shared between the two rings. In marked contrast, compound 3 has 
one carbon-carbon bond of imidazole fused with the six-membered ring so that none of 
the nitrogen atoms is shared. In addition, the six-membered ring possesses an amine 
group in the ring. Since size and geometry of these three structures are very close to each 
other, they are often pursued closely in biomedical research. 
 
Figure 3. Fusion of piperidine and imidazole rings to give core structures; 5,6,7,8-
tetrahydroimidazo[1,5-a]pyridine (1), 5,6,7,8-tetrahydroimidazo[1,2-a]pyridine (2), and 





1.2.1  Synthetic Routes 
The focus of this review is based primarily on the synthesis of core structure 1, 
and will occasionally cover core structures 2 and 3 for comparison purposes accordingly. 
The synthetic routes for synthesizing THIP are a multi-step processes, influenced by the 
type of core structure, the substituents and the position of the substituents. There are 
different approaches used in the synthesis of 1, and this review will be primarily 
discussing five of them as shown in Figure 4. Substituents can bond to the core structure 
1 at the 1- and/or 3-position(s) of the imidazole ring, and at the 5-, 6-, 7- and/or 8-
position(s) in the piperidine ring (Figure 4). Hereafter, the positioning numbers on 1 
(Figure 4) will be used to indicate the position of substituents.    
 
Figure 4. Synthetic routes for synthesis of 5,6,7,8-tetrahydroimidazo[1,5-a]pyridine. The 
numbering corresponds to atoms in core structure 1. (*) represents the positions at which 




1.2.1.1  Nucleophilic Substitution: SN2 Ring Closure of Activated 4-(3H-Imidazol-4-
yl)-1-Butanol Derivatives 
The synthesis of 7 by the nucleophilic substitution method is a five-step process 
resulting in aromatic substituent in the 5-position as shown in Scheme 1. The preparation 
of the activated 4-(3H-imidazol-4-yl)-1-butanol (6) begins with the protection of methyl 
4-(1H-imidazol-4-yl)butanoate 4 with triphenylmethyl chloride and subsequent reduction 
with di-isobutylaluminum hydride (DIBAH) to yield the corresponding aldehyde (5). The 
aromatic ring is introduced with the lithium dianion that is derived from 4-bromo-N-tert-
butylbenzenecarboxamide. The activated secondary benzylic alcohol 6 is chlorinated with 
thionyl chloride in refluxing methylene chloride, resulting in subsequent intramolecular 
cyclization via a SN2 process. The quartanized intermediate is treated with refluxing 
methanol to remove the triphenyl (Tr) protecting group on the nitrogen, to give 7. 
 
Scheme 1. Reaction scheme for the synthesis of 7 via nucleophilic substitution. (i) 
Ph3CCl, Et3N, CH2CN, reflux; (ii) 2.0 eq of DIBAH, CH2Cl2, -78
oC; (iii) 4-LiPhCONLi-
Bu-t, THF, -78oC; (iv) 3.0 eq of SOCl2, CH2Cl2, Reflux; (v) CH3CN, reflux (6). 
 
 This method was used by Browne and co-workers in their synthesis of aromatase 
inhibitor fadrozole hydrochloride (6). The essence of reaction is to have the pyridyl 
nitrogen of imidazole as nucleophile to attack the carbon which has chlorine present as a 




1.2.1.2  Cyclocondensation: Intramolecular Cyclization of an Iminium Ion via 
Electrophilic Aromatic Substitution  
The synthesis of 13 via the cyclocondesation is a one-step process with the 
substituents in the 3-, 5- and 8-positions. The synthesis of the precursor 12, however, is a 
five-step process. The presence of a substituent in the 3-position forces the 
cyclocondesation reaction to give the [1,5-a]THIP (1) as oppose to [1,2-a]THIP (2) (8). 
 
Scheme 2. Reaction scheme for the synthesis of 13 via cyclocondensation (8). 
 
In the preparation of the aldehyde (12), the alcohol in 3-chloropropanol (9) is 
protected and the chlorine is substituted to give the activated iodine (10). The benzylic 
imidazole is treated with lithium base to give the organolithium that is then alkylated by 
10 to produce 11. The silyl ether is then deprotected in 11 followed by Swern Oxidation 
to give the desired aldehyde (12). The condensation reaction between 12 and amine 
results in the formation of the iminium ion intermediate (12a) that then undergoes 




average yield. The process results in the formation of cis- and trans-isomers (8). In this 
route, an electron-rich carbon from imidazole attacks a masked carbon cation (an 
iminium ion), followed by E1 elimination of proton to complete the formation of core 
structure. Strictly speaking, such cyclocondensation results from the nucleophilic 
addition. 
1.2.1.3  Cycloaddition: [2+2+1] Cycloaddition between Nitrile and Azido Alkyne 
using AuCl3 Catalyst  
In the synthesis of 15 via the [2+2+1] cycloaddition, a gold catalyst is used with 
the substituents forming in the 3-position (14). The carbon length between the two 
terminal groups in the azidoalkyne can be manipulated to facilitate the desired ring 
formation. Additional substituents can be manipulated at 5-,6- and/or 7-position by 
varying the azidoalkyne used.  
There are two competing intramolecular reactions taking place between the nitrile 
and azidoalkyne, the Huisgen [3+2] and a [2+2+1] cycloadditions (Scheme 3). The 
presence of gold catalyst favors the latter cycloaddition. The reaction begins with a 5-
exo-dig cyclization of the tethered azido group onto a gold activated terminal alkyne to 
give 14a which then leads into the formation of the activated α-imino gold carbene 
intermediate 14b upon dinitrogen expulsion (15). The highly electrophilic carbene 14b 
then reacts with the weakly nucleophilic nitrile to form a nitrile-ylide type intermediate 
14c, which then cyclizes to give the bicyclic imidazole 15. The formation of imidazole 




plays a key role as it minimizes the competing intramolecular [3+2] cycloaddition, 
Huisgen reaction, to give the desired bicyclic imidazole 15 in good yield (14). 
 
Scheme 3. Reaction scheme and mechanism for the synthesis of 15 via cycloaddition 
using gold catalyst (14). 
 
 1.2.1.4  Oxidative Radical Cyclization 
The synthesis of 18 via oxidative radical cyclization is a two-step process that 
results in the formation of substituent in the 1-position. The use of imidazo-4-
carbaldehyde is vital for the cyclization to occur. The first-step of the reactions begins 
with the alkylation of the nitrogen on the imidazole ring (16) with excess dibromoalkane 
to give the desired N-alkylated product (17). The formation of the ring size varies based 




formation of the six-membered ring. The oxidative radical cyclization is highly selective 
for the formation of the six-membered ring resulting in no side products (16). The 
electron-withdrawing aldehyde group is vital as the nucleophilic alkyl radical attacks the 
β-position of the α,β-unsaturated aldehyde moiety in a Michael type manner.   
 
Scheme 4. Reaction scheme and mechanism for the synthesis 18 via oxidative radical 
cyclization (17). 
 
There is no definitive mechanism for the oxidative radical cyclization using 
tributyltin hydride (Bu3SnH). However, examples reported in literature suggest that the 
formation of an aromatic product is the driving force. In the oxidation radical cyclization, 
the radical, 17a is formed by the abstraction of bromine by Bu3SnH. The radical attacks 
the ring to give the π-radical stabilized intermediate 17b. The abstraction of hydrogen is a 




in solution to give the aromatic product 18. A low yield of 49% has been reported using 
this process (16, 17).  
1.2.1.5  Catalytic Hydrogenation 
The reduction process via catalytic hydrogenation is the most widely used 
technique for the synthesis of THIP, 1.  Reduction of either imidazo[1,5-a]pyridine (19)  
(18) or dihydroimidazo[1,5-a]pyridine (20) (19) results in the formation of  21.  It is a 
simple and clean reaction. 
 
Scheme 5. Reaction scheme for the synthesis of 21 via catalytic hydrogenation. 
 
Reduction of IMP is an attractive process as there are multiple ways of 
synthesizing IMP with substituents in different positions on the IMP. Reduction is carried 
out using catalytic hydrogenation, a process that will be discussed in details in the next 
section. The reducing agent is molecular hydrogen gas (H2) and the catalyst used is either 
Pd/C or PtO2 (6, 12, 13). 
Whether it is facile to construct the core structure with desirable components 
depends on the readiness of starting materials. It is worth mentioning that all the methods 




through multi-step synthesis. For example, starting material 4 as discussed in the first 
route is not a substrate commercially available. This means that it will take even more 
steps to accomplish the target structure from a commercially available substrate because 
4 needs to be made available first. In the second route, i.e., cyclocondensation, the 
preparation of alkyl aldehyde such as 12 involves a long process as evident in Scheme 2.    
In the [2+2+1] cycloaddition method, it uses an expensive reagent, AuCl3, and an 
unusually reactive substrate, azidoalkyne. Again, the synthesis of azidoalkynes involves a 
tedious process. Although the catalytic hydrogenation process is straightforward, the 
synthesis of imidazo[1,5-a]pyridines is not (20). The use of hydrogen gas does present an 
inconvenient challenge in the reaction manipulation. However, it does offer an 
opportunity to explore new ways for the catalytic hydrogenation. 
1.2.2 Structural Isomers Application 
The first THIP was synthesized in 1972 in a study conducted by Kametani to 
determine its biological activity as an analgesic drug (9).  Since then there have been 
several other forms of THIP that have been synthesized and applied in a wide array of 
medicinal and biological studies. As stated earlier, the benefit of using THIP is the ability 
of the imidazole moiety to mimic well known biological components of human organism 
(Figure 1). This section covers the history and application of the different structural 





In 1972, Kametani and co-workers in their biochemical study of developing novel 
analgesic (pain relieve)  drug in the Central Nervous System (CNS), synthesized 5-
(hydroxymethyl)-2-methyl-4-(4,5,6,7-tetrahydro-3H-imidazo[4,5-c]pyridin-4-yl)pyridin-
3-ol (Figure 5, 22) (9). It has the 3 isomer as its core structure, and is synthesized by the 
cyclization of pyridoxal molecule with histamines in ethanol. The compounds were 
synthesized as a derivative of histamine and were found to be effective as an analgesic 
drug (9). 
 
Scheme 6. Synthesis of 5-(hydroxymethyl)-2-methyl-4-(4,5,6,7-tetrahydro-3H-
imidazo[4,5-c]pyridin-4-yl)pyridin-3-ol (22) (9). 
 
In 1973, Durant and co-workers first synthesized the 1 and 2 isomers of THIP, 23 
(72%) and 24 (67%) respectively, to evaluate it as a potential histamine H1- or H2-
receptor antagonist/agonist (18). Of the two, compound 24 showed appreciable activity as 
a H1-receptor agonist. Compounds 23 and 24 were synthesized by the catalytic 
hydrogenation of imidazo[1,5-a]pyridine and imidazo[1,2-a]pyridine respectively (18) 
using palladium on carbon (Pd/C) and platinum dioxide (PtO2) as a catalyst. The 




Davey et al. used a similar procedure in the synthesis of 25, however, instead of using 
imidazo[1,5-a]pyridine as reagent he used dihydrate imidazo[1,5-a]pyridine, that he 
synthesized using a novel process, involving reaction between either a phenyl 
cyclopropyl ketone or 4-halobutyrophenon with excess imidazole (19). The compound 25 
was used in the biological study as a potential cardiotonic agent and was proven to have 
positive inotropic activity, i.e., the ability to strengthen the muscular contraction of the 
heart (19).  
 
Scheme 7. Synthesis of 2-(5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-1-yl)ethanamine (23) 
(18), 2-(5,6,7,8-tetrahydroimidazo[1,2-a]pyridin-2-yl)ethanamine (24) (18), and 1-aryl-3-





In 1988, Lattrell and co-workers used IMP and THIP as a variant for heterocycles 
(R) of the cefpirome analogs (Scheme 8) to determine their activities as anti-bacterial 
agents (13). Similar to Durant’s method of catalytic hydrogenation of IMP to THIP, 
Lattrell et al. used platinum dioxide (PtO2) as the catalyst in the presence of 
trifluoroacetic acid (TFA) solvent to synthesize 26 & 27 (Scheme 8a). THIP was then 
added to cefotaxime to give cefpirome analogs 28 and 29.  Lattrell was the first to 
develop and use THIP as a cation salt. 
 
Scheme 8. (a) Catalytic hydrogenation of IMP derivatives to give THIP. 26 and 27 were 
collected as colorless oil with, 93 % and 99% purity, respectively. (b) Synthesis of 
cefpirome analogs, 28 and 29 (13). i. Cefotaxime (2 mmol), BSTFA (7.2 mmol) in 
CH2Cl2. Iodotrimethylsilane (TMSI) (5.2 mmol) was added, stirred, evaporated and the 





The cefpirome analogs 28 and 29 showed decreased activity towards 
Pseudomonas and Enterobacter cloacae P99 and exhibited good activity against Gram-
positive bacteria in comparison to other cefpirome analogs (13). 28 showed excellent 
activity against the K1 β-lactamase producing Klebsiella aerogenes 1082 E strain (13).   
Soon after in 1991, a major breakthrough by Browne and co-workers led to the 
discovery of fadrozole hydrochloride (30), which is a potent, selective non-steroidal 
inhibitor of aromatase for treatment of estrogen dependent diseases (6). Estrogen is 
implicated in the progression of many diseases. Subsequent antagonism of estrogen or 
lowering its circulating level is thought to be relevant to therapy for disorders such as 
estrogen-dependent breast cancer, gynecomastia, systemic lupus, erythematosus, and 
premature labor (6). There are two ways to antagonize estrogen or lower its circulation, 
estrogen receptor antagonism and aromatase inhibitor (6). The enzyme aromatase is a key 
enzyme for the synthesis of estrogens. It is responsible for the aromatization of androgens 
into estrogens. It occurs in the adipose tissue, brain, testes and ovaries. It’s a membrane-
bound microsomal complex that contains the NADP cytochrome c reductase and the 
cytochrome P-450 units.  
Upon investigation Browne discovered that compound 30 binds competitively and 
reversibly with aromatase (Figure 5b) (6) and that the pyrimidine nitrogen N2 of 30 
coordinates with the iron (Fe) of the porphyrin. It was proposed that the strong interaction 
could be due to the interaction between the fused rings and the active site. It was 




in the active site increasing its selectivity (6). Compound 30 was synthesized via SN2 ring 
closure of an activated 4-(3H-imidazol-4-yl)-1-butanol derivative (Scheme 9). 
 
Figure 5. (a) Structure of 4-(5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl)benzonitrile 
(30) more commonly known as fadrozole hydrochloride. (b) Proposed interaction of 30 







Scheme 9. Reaction scheme for the synthesis of 30 via nucleophilic substitution (6). (i) 
Ph3CCl, Et3N, CH2CN, reflux; (ii) 2.0 eq of DIBAH, CH2Cl2, -78 
oC; (iii) 4-LiPhCONLi-
Bu-t, THF, -78 oC; (iv) 3.0 eq of SOCl2, CH2Cl2, reflux; (v) CH3CN, reflux; (vi) SOCl2, 
reflux. 
 
In the same year, Ohta et al. released a patent in which they synthesized multi-
substituted core structure of 1 and 2, analogs 35 and 36, respectively (Scheme 10) (21). 
They claimed that analogs 35 and 36 were useful in preventing or treating hypersensitive 
intestinal syndrome, i.e., irritable bowel syndrome by the antagonism against 5-
hydroxytrptamine type 3 (5-HT3) receptor (21). The receptor 5-HT3 is a member of the 
Cys-loop family of ligand-gated-ion-channels. It is activated by the binding of the 
neurotransmitter, serotonin, that leads to permeability of potassium (K), sodium (Na) and 




enhancing gastrointestinal motility by either increasing frequency of contractions in the 
small intestine or making them stronger (22). The THIPs, compounds 35 and 36, were 
synthesized using Durant’s method of catalytic hydrogenation of imidazopyridines, using 
a Pd/C catalyst. The addition of hydrochloric acid transforms the ester group (-CO2CH3) 
to carboxylic acid (-COOH) as seen in the transformation of compound 39 to 40.  
 
Scheme 10. (a) General structure of compounds 35 and 36 used for treatment of 
hypersensitive intestinal bowel syndrome. (b) Synthetic scheme for the synthesis of THIP 
compounds, 39 and 40 (21).  
 
In 1995, Pelet and co-workers used the commercially synthesized non-peptide 
hormone 41 to study its effect as an antagonist to angiotensin-II receptor (10). 
Angiotensin is a peptide hormone that leads to increase in blood pressure by causing 
contraction of muscular walls of large arteries and small arterioles (10). Binding of 41 to 
angiotensin-II receptor reduces the contraction of portal vein smooth muscle induced by 
angiotensin-II. Complete reduction of angiotensin-II induced contraction, is observed 





Figure 6. Structure of 1-(1-(4-(dimethylamino)-3-methylbenzyl)-6,7-dihydro-1H-
imidazo[4,5-c]pyridin-5(4H)-yl)-2,2-diphenylethanone (41) used in lowering blood 
pressure by interacting with angiotensin II receptor (10). 
 
Dinsmore and co-workers in 2000 synthesized conformationally constrained 1, 
trans-42 and cis-43, that were evaluated as inhibitors of farnesyltransferase (Ftase) (8). 
Ftase is a post-translation processing enzyme that prenylates proteins and enables them to 
participate in signal transduction during cell proliferation (8). Inhibitors of Ftase are used 
as promising anti-tumor agent. Compounds 42 and 43 were found to have diminished 
Ftase inhibitory activity but increased pharmacokinetic property (T1/2 >10h) (8). THIPs 
were synthesized via cyclocondensation reaction (see Scheme 2).  
 





Bridger in 2004 synthesized and patented 44 as a heterocyclic compound that 
binds to chemokine receptors. Chemokines are signaling proteins that are principle 
mediators in initiation and maintenance of inflammation (11). Bridger claims that the 
binding of 44 to chemokine receptor could demonstrate protective effects against 
infections of target cells such as human immunodeficiency virus (HIV). He synthesized 
the [1, 5-a]THIP moiety using Lattrell’s method. 
 
Figure 8. Structure of N1-((5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-3-yl)methyl)-N1-
(5,6,7,8-tetrahydroquinolin-8-yl)butane-1,4-diamine (44) (11). 
 
In 2009, Elder linked moiety 45 to β-carbolines 46, a known inhibitor of the 
enzyme, nuclear factor kappa-B kinase subunit beta (IKK2) (23).  The enzyme IKK 
participates in phosphorylation of the protein IKB that participates in many biological 
pathways. Inhibitors of IKK prevent the phosphorylation of IKB and its subsequent 
downfield effects thus being useful in treating cancer, inflammatory disease and immune-
related diseases (23). Compound 46 is synthesized using carbaldehyde-THIP (45). The 




method of reduction of IMP and then functionalized to give carbaldehyde by reacting 
THIP with n-butyl lithium (n-BuLi) and N,N-dimethylformamide (DMF).     
 
Scheme 11. Synthetic scheme for the synthesis of 46 via reaction between 45 and β-
carboline, which is a known inhibitor of IKK2 (23). 
 
Carcache et al. in 2011 conducted the structure activity relationship (SAR) study 
of benzimidazole as potent and orally active mGlu5 receptor antagonist and used 47 as a 
lead for optimization (24). For the synthesis of 49, THIP was brominated using 
bromonitrile (BrCN) to give 47. Suzuki coupling with 48 resulted in the desired product 
49. However, in their metabolic study the metabolic oxidation of the six-membered fused 
ring leads to ring opening to give 50, making it an ineffective antagonist of mGlu5 
receptor. This led Carcache et al. to use benzimidazole as a potent antagonist of mGlu5 





Scheme 12. (a) Synthesis of 2-chloro-N-(4-chlorophenyl)-4-(5,6,7,8-
tetrahydroimidazo[1,5-a]pyridin-3-yl)anilin (49) used as lead compound to synthesize 
potent mGlu5 receptor antagonist 2-chloro-4-(7-chloro-1-propyl-1H-benzo[d]imidazol-2-
yl)-N-(4-chlorophenyl)aniline using benzimidazole (24). (b) Metabolic oxidation of 49 
results to ring opening leading to 50. 
 
Another key discovery was the synthesis of imidazosugars. Deredas et al. in 2007, 
were able to synthesize imidazosugar (51) using the Wittig and dihydroxylation reactions 
(25). Compound 51 was discovered to be a potential inhibitor of α-D-galactosidase. The 
presence of the -CH2OH group trans to the hydroxy group in 51 was important to the 
inhibition of α-D-galactosidase. In 2011, Li was able to successfully synthesize a series 




inhibiting β-glucosidase (26). The enzyme is also referred to as glycosidase hydrolase 
and is involved in the hydrolysis of sugar. Inhibition of glycosidase leads to widespread 
application in the treatment of diabetes, viral infection, metastatic cancer, and lysosomal 
storage disease (26, 27). 
 
Scheme 13. (a) Structure of imidazosugars (5R,7S,8R)-5-(hydroxymethyl)-5,6,7,8-
tetrahydroimidazo[1,5-a]pyridine-7,8-diol (51) (25) and (5S,6S,7R,8R)-5-
(hydroxymethyl)-2-(4-methylphenethyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine-6,7,8-




Based on SAR study conducted by Li, 52 was the most effective in inhibiting the 
enzyme, by mimicking the transition state (Scheme 13b). As seen in Scheme 13b, the 
hydrolysis of β-glycoside sugar by the enzyme glycosidase results in the formation of 
oxocarbenium ion-like transition state. Imidazosugar 52 mimics the sugar β-glycoside in 
a similar manner at the transition state. The presence of non-hydrolyzable glucosidic CN 
bond between the anomeric carbon and N1 of imidazole, and their anomeric carbon 
display sp2 hybridization (26). The ground state of 52 mimics the assumed half-
chair/envelope conformation of the sugar ring in the transition state resulting from the 
fusion of imidazole ring to the sugar (26). The protonation of the imidazole ring 
effectively mimics the charge distribution of oxocarbenium ion. The lone pair on N1 of 
imidazole participates in lateral protonation with the acid/base residue (26). The presence 
of the -(CH2)2Ph group at C2, significantly improves inhibitory property by effectively 
binding to the active site. The synthesis of 51 and 52 is a multi-step process (Scheme 
13c). That uses readily available sugar α-D-glucopyranoside as the starting material. 
Jiang and co-workers in 2012 were able to successfully synthesize Nagleamide K 
(53) that is a secondary metabolite from the marine sponge-family with the potential 
antimicrobial activity (12). The [1,5-a]THIP forms the core of Nagelamide K and was 





Figure 9. Structure of N,N'-(((5S,6R,7R)-5-(1H-imidazol-4-yl)-5,6,7,8-
tetrahydroimidazo[1,5-a]pyridine-6,7-diyl)bis(methylene))bis(4,5-dibromo-1H-pyrrole-2-
carboxamide) (22) commonly known as Nagleamide K an anti-microbial agent (12). 
 
Recently, there has been an interest in the use of THIP as an anti-cancer drug. 
Brookings and co-workers filed a patent in which derivatives of [4,5-c]THIP (54) were 
being synthesized and used as modulators for tumor necrosis factor (TNFα) activities 
(28). TNFα belong to a group of superfamily of proteins that share primary function of 
regulating cell survival and cell death. 
 





Since the inception of THIP in 1971 as an analgesic drug, the application of THIP 
has been expanded in a wide array of medicinal and biological fields, and has been used 
as anti-cancer (6-8), anti-inflammatory (9), anti-hypertensive (10), anti-microbial (11, 
12), and anti-bacterial agents (13). Majority of THIPs medicinal and biological 
applications stems from its interaction with enzymes and receptors that participate in key 
biological pathways. For example, the binding of fadrazole hydrochloride (30) to the 
enzyme aromatase results in the lowering of estrogen in the blood. Estrogen is implicated 
in the progression of many diseases such as breast cancer, gynecomastia, systemic lupus, 
erythematosus, and premature labor (6), thus leading to a potential cure of estrogen-
dependent diseases. Similarly, the inhibition of enzymes such as Ftase, IKK, α-D-
galactosidase and β-glucosidase leads to the treatment of many diseases. The 
advancement of synthetic procedures and innovative variants of THIP synthesized such 
as imidazosugars, 51 and 52, have led to further development of its application capability. 
THIP continues to show promising results in biological and medicinal applications.  
1.3 Reduction 
Reduction reactions are one of the important reactions in synthesis. Reduction in 
inorganic chemistry is defined as gain of one or more electrons by an atom whereas in 
organic chemistry it defined as gain of electron density by carbon (29). This is 
accomplished by either bond breaking between carbon and a more electronegative atom 
or bond formation between carbon and a less electronegative atom. Reduction is 




or removal of oxygen or other electronegative substituents. The opposite is true for 
oxidation reaction, in which the loss of electron density of carbon results in oxidation.  
 
Figure 11. Oxidation levels of some common types of compounds. 
 
A list of compounds of increasing oxidation level is seen in Figure 11. Carbon 
dioxide (CO2) has the highest oxidation level as a result of carbon having maximum 
number of C-O bonds. Alkanes (CH4) have the lowest oxidation level as result of carbon 
having maximum number of C-H bonds. The direction of reaction from high to low 
oxidation level is known as reduction and vice-versa, the direction of reaction from low 
to high oxidation level is oxidation. The most widely used methodology for adding 
hydrogen to carbon is by catalytic hydrogenation (30).  
1.3.1 Catalytic Hydrogenation 
The reduction of functional groups with hydrogen gas is one of the most 
important reactions in organic chemistry, dating back to the first hydrogenation of ethene 




alkenes, ketones, aldehydes, nitriles, nitro-groups and aromatic rings. There are two key 
components to carry out catalytic hydrogenation, a hydrogen source and a catalyst. 
Reactions can proceed with catalytic amounts of transition metals particularly platinum 
(Pt), palladium (Pd), rhodium (Rh), ruthenium (Ru) and nickel (Ni). The functional group 
that is reduced, the extent of reduction and product distribution are dependent on the 
nature and amount of catalyst used and the type of hydrogenation process (29, 31).  
There are two major categories of catalysts: homogeneous and heterogeneous. 
Homogenous catalysts are soluble in the reaction medium and present in one phase (29). 
Heterogeneous catalysts on the other hand, are insoluble in the reaction medium and 
present in a second phase, resulting in two phases in reaction system. Phase refers to 
solid, liquid or gas. In most heterogeneous hydrogenation reactions, the catalyst is in 
solid phase while the reaction medium is in liquid phase.  
Heterogeneous hydrogenation can be carried out on a supported or unsupported 
medium. In supported heterogeneous hydrogenation, the catalyst is adsorbed or admixed 
to an inert material such as carbon (ex: Pt/C, Pd/C) or alumina (Rh/Al2O3) (31). The 
support dilutes the expensive transition metal catalyst thus controlling the rate of 
reaction, and making it cost-effective. The benefit of using a support is that in most cases, 
it lessens the reactivity of the catalyst, preventing over-reduction from taking place 
increases selectivity towards functional groups being reduced. In most cases 




There are two strategies employed in addition of hydrogen to a target substrate: 
direct hydrogenation (DH) and transfer hydrogenation (TH) (32). In the DH method, 
hydrogen gas is introduced to a system directly at a certain pressure and temperature. In 
the TH method, a non -hydrogen gas source is used, i.e., the hydrogen gas is presumed to 
be generated in-situ mostly in presence of a catalyst (Scheme 14). In recent years, the TH 
method has been the chosen hydrogen source as it does not require hazardous pressurized 
H2 gas or its elaborate experimental setups; the hydrogen donors are easy to handle, 
inexpensive, and readily available. The major side products can be recycled (32, 33). A 
key advantage to using TH is the ability to control the rate and specificity of reduction 
through the amount of hydrogen donor and source (33). 
Common reducing agents that employ TH are hydrazine, cyclohexene, 
cyclohexadiene, diamide, formic acid and ethanol to name a few (34). Of the reducing 
agents, hydrazine hydrate is most widely used. Hydrazine hydrate is liquid over wide 
range of temperatures (213-392 K) and it is a promising material for hydrogen storage 
(35). On decomposition in the presence of transition metals (Pd, Pt, Sn, Ir, Rh, Ru), it 
releases hydrogen and nitrogen gas (Scheme 14). Both of which are non-toxic, and does 
not need elaborate techniques to collect gas (35).  
 





Key factors that influence the reduction include catalysis agglomeration, 
temperature of the reaction, catalyst poisoning, the ratio of hydrogen compound to the 
compound being reduced, the pressure of hydrogen gas, preparation method, the age of 
the catalyst and the number of times the catalyst has been recycled (31). The selectivity 
and reactivity of a heterogeneous catalyst is greatly influenced by the type of metal used, 
the amount of metal adsorbed on the surface and the surface structure/morphology of the 
catalyst. The surface of the metal catalyst is very porous thus allowing hydrogen gas and 
substrates to be adsorbed. The active sites of the catalyst are defined as regions in which 
the catalyst can bind to hydrogen and/or substrates. The rate of hydrogenation is directly 
proportion to the number of active sites available, i.e., if the number of active sites 
increases then the rate of hydrogenation increases as well. The activity of active sites can 
also decrease if it is either blocked by gases such as carbon dioxide and carbon monoxide 
or if a poison binds to it irreversibly in preference to the substrate or hydrogen such as 
bivalent sulfur (36).  
The structure/morphology of the catalyst greatly influences the reactivity and 
selectivity of the functional groups to be reduced. There are three orientations in which 
metal orients itself on the support (Figure 12) (37): terrace, edge and corner. Their 
orientation is influenced by type of metal used and its coordination state. The terrace-type 
atom (A) is positioned in the middle of a flat terrace of the support and is surrounded by 
ligands, and their geometry corresponds to ML5 with one free coordination site. The 
edge-type atom (B) is positioned on the steps or edges of the support with their geometry 




(C) is positioned to the kink or corner of the support and is surrounded by six neighboring 
atoms with their geometry corresponding to ML3, and having three free coordination 
sites. As the number and types of neighboring atoms around the type of atoms change, the 
binding capacity will change as well. Large particle size favors terrace atoms and small 
particle size favors corner atoms (37).      
 
Figure 12. The surface and particle site for heterogeneous catalyst on a flat and curved 
surface; terrace (A) edge (B) and corner (C) type metals (numbers corresponds to 
neighbors) (37). 
 
1.3.2 Reduction of Alkenes, Aromatic and Heteroaromatic Hydrocarbon 
In the reduction of alkenes, aromatic, and heteroaromatic hydrocarbon, catalytic 
hydrogenation is widely used. Irrespective of the substrate and catalyst used, many 




1. Adsorption of hydrogen and organic substrate on the active site of metal via 
oxidative addition. Substrate coordinates to the metal via π-bond or lone pairs of 
electrons. 
2. Transfer of hydrogen from metal to substrate. Substrate coordinates to the metal 
via σ-bond.   
3. Desorption of reduced organic substrate from active site via reductive elimination, 
which is syn-addition (same side) of hydrogen. 
 
Scheme 15. Mechanistic description of alkene reduction (34). 
  
The ability of the catalyst to adsorb hydrogen and organic substrate, to facilitate 
transfer of hydrogen to substrate and to remove substrate are key parts of the catalyst in 
the reduction process. The selection of a catalyst is of primary importance as it 
determines the extent of reduction and the groups to be reduced or hydrogenolyzed. 
Substrates and the secondary functional group of the substituents also play a key role in 




1.3.2.1  Selective Hydrogenation of Aromatic and Heteroaromatic Compounds 
Of the different compounds to reduce, the hydrogenation of aromatic and 
heteroaromatic compounds are presumably the most difficult to reduce to the saturated 
form, due to the following reasons (38): 
(1) High stability of aromatic compounds. 
(2) Deactivating and/or poisoning of catalyst by heteroaromatic compounds 
containing nitro and sulfur. 
(3) Lack of secondary coordinating group in simple aromatic compounds to interact 
with catalyst.  
(4) Hydrogenation of pro-chiral aromatic rings resulting in racemic mixture. 
(5) The use of rigorous condition such as elevated temperatures and pressures to 
hydrogenate more than one type of bond simultaneously. 
There have been efforts made through the years to successfully hydrogenate 
aromatic compounds that lead to selectivity towards a single enantiomer (Scheme 16). 






Scheme 16. Effect of additives on activation of (a) catalyst (39) and (b) substrate (40). 
 
The success of asymmetric hydrogenation depends mainly upon the substrate and 
catalyst activation (Figure 13). Catalysts are activated by the addition of certain additives 
and by tuning electronic and steric properties of chiral ligands that lead to asymmetric 




bicyclic aromatic compounds, activators that disrupt aromaticity, and secondary-
coordinating group also known as anchoring groups (Scheme 16b). Bicyclic aromatic 
compounds are known to have weak aromaticity and are thus beneficial as they decrease 
the aromatic stabilization of heteroaromatic ring, thus increasing the reactivity of these 
substrates towards hydrogenation (41).  
 
Figure 13. Strategies for asymmetric hydrogenation of aromatic compounds (40). 
 
The effect of additives on the activation of catalyst and substrate is illustrated in 
Scheme 16. In the selective hydrogenation of quinoline by the iridium catalyst (Scheme 
16a), iodide activates the iridium catalyst by oxidizing it from Ir(I) to the catalytic active 
state Ir(III) (39). The presence of a chiral ligand (R)-MeO-BiPhep favors the addition of 





 In the selective hydrogenation of indoles by the Pd-catalyst (Scheme 16b) (40), 
the presence of the Bronsted acid, L-camphorsulfonic acid (L-CSA), functions as an 
activator. L-CSA could react with the indole to form iminium salt by the protonation of 
the carbon-carbon double bond. The protonation partially destroys aromaticity of the 
indole ring, resulting in the in-situ formation of an iminium salt and its subsequent 
hydrogenation. In indole and quinoline, the benzyl molecule is fused to the ring, leading 
to decrease in the aromatic stability of the ring thus promoting the hydrogenation of the 
ring. 
There are two key features in the substrates that increase efficacy of reduction: 
accessibility and electron density (29, 42). The ease of accessibility of the double bonds 
in aliphatic and aromatic hydrocarbons to the active site of catalyst favors reduction to 
take place. In the latter situation, the presence of high electron density in the rings 
increases coordination with the metal surface via lone pairs or π-bond interaction. As a 
result, the catalyst prefers to reduce the rings that are electron rich as opposed to electron 
poor by the presence of electron withdrawing substituents. In the reduction of 1-
napthalenecarboxylic acid (55) with Raney nickel, of the two rings the electron rich ring 
was selectively reduced as opposed to the electron poor aromatic ring with the carboxylic 
acid (42). However, it seems that the selectivity is rather unique as well in the 
heterocyclic aromatic systems. For example, carboxylate-IMP (38) is reduced to 
carboxylate-THIP (39) in the presence of Pd/C & H2 (Scheme 10). The reduction of 





Figure 14. Selective reduction of electron rich aromatic ring in 1-naphthalenecarboxylic 
acid (55) (42). 
 
Another phenomenon that commonly influences the stereochemistry of the alkene 
and the aromatic system is haptophilicity also known as the anchoring effect (43), in 
which the functional group binds to the surface of catalyst and influences the delivery of 
hydrogen from the same side of the molecule. The steric and electronic effects of the 
anchoring haptophile group influence the side in which the adsorption of hydrogen will 
take place on the substrate (43).  
There are three modes of adsorption of haptophile group on the metal surface as 
illustrated in Figure 15 (43). In the first mode (Figure 15a), the anchor group results in 
steric interaction with the surface, hindering the adsorption of substrate onto the metal 
surface cis to the anchor group. In the second mode (Figure 15b), the anchor group does 
not bind to the metal surface mainly due to steric hindrance, as a result the substrate gets 
adsorbed trans to the anchor group resulting in transfer of hydrogen opposite to that of 
the anchoring group. In the third mode (Figure 15c), the anchor group binds to the metal 
surface and facilitates the adsorption of substrate cis to the anchor group resulting in 
transfer of hydrogen on the same side to that of the anchor group. The anchoring of 





Figure 15. Modes of adsorption of anchoring group on the surface of catalyst (43). 
 
The stereoselectivity of hydrogenation is affected by the presence of the polar 
functional group. For instant, in the reduction of 57a, the presence of hydroxy group 
results in the same side addition of the hydroxy group, implying that the hydroxy group is 
interacting with the catalytic surface to give cis stereochemistry (58a). In  the reduction 
of 57b,the presence of the ester group results in the addition of hydrogen opposite to the 
ester group to give trans stereochemistry (59b) (34, 43). 





Most functional groups with the exception of carboxyl functional groups are 
usually hydrogenated prior to the aromatic rings. For the hydrogenation of aromatic and 
heteroaromatic, Rh >Ru>Pt>Ni>Pd are preferred choice, however, the order of activity 
changes for other substrates and types of functional groups present. Pd is preferred 
catalyst for the reduction of alkenes, Rh and Ru for the aromatic ring, and Pt or Pd are 
highly favored for the reduction of heteroaromatic hydrocarbon (44).  
Substrates can bind to the metal surface reversibly and irreversibly. Irreversible 
binding of substrates, mainly those containing bivalent sulfur leads to the poisoning of 
catalyst by deactivating it (29). Substrates that bind to the metal surface reversibly do so 
by coordinating to the metal via π-bond or lone pairs of electrons on the heteroatom 
functional groups (34).  
The presence of other functional groups can complicate the reduction process. 
The functional group can either be reduced or hydrogenolyzed. Hydrogenolysis is a 
process in which the functional group is replaced by hydrogen. For the hydrogenolysis of 
halogens, Pd is the preferred catalyst (44). The process of hydrogenolysis is slow, and 
poor yield is observed as one goes up the row in the periodic table. The mechanism in 
which hydrogenolysis occurs is seen in Scheme 18. The Pd catalyst is fused between the 
halogen and the substrate via oxidative addition (61). The hydrogen atom then 
coordinates with the Pd (62), and is transferred to the substrate (63) which is removed via 





Scheme 18. Hydrogenolysis of bromine from aromatic ring by Pd (44). 
 
In the reduction of aromatic rings, Rh and Ru are used to avoid hydrogenolysis. 
However, in the presence of fused rings when only one ring needs to be reduced, Pd is 
used instead (44). In the reduction of naphthalene (64) by the Rh catalyst, tetralin (65) is 
first formed and on further reduction leads to the formation of decalin (66). However, 
replacing the Rh catalyst with Pd results in the formation of only tetralin (65) which can 
be attributed to the slowness of Pd to further reduce the aromatic ring to form 66.  
 




1.3.3 Reduction of Aryl-Nitro to Aryl-Amine 
Aryl-amines are important synthetic intermediates in bioactive compounds such 
as agrochemicals, dyes, medicine, and polymers (45). They are used as precursors for 
synthesis of other nitrogen-containing compounds such as amide, imine, azo compounds, 
isocyanate, and diazonium salts. Some of the nitrogen-containing compounds can then be 
converted to various other functional groups (Figure 16) (45). The most common 
methodology for synthesizing aryl-amine is through the reduction of aryl-nitro. Aryl-nitro 
is synthesized quite readily by the process of nitration of simple aromatic compounds 
(46). Reduction of aryl-nitro offers the shortest and easiest way for synthesizing 
substituted aryl-amines.  
 




There have been a vast variety of procedures involving metals and reducing 
agents used for the reduction of aryl-nitro compounds to corresponding aryl-amine 
(Scheme 20). Among them the traditional reduction using iron and hydrochloric or acetic 
acid is still important (47). Other methodologies that involve dissolving metals such as 
Zn (48) and Sn (49) in presence of hydrochloric acid are also employed. Other reagents 
such as SnCl2/H2O (50), SnCl2/ionic liquid (51), N2H4/FeCl3 (52), N2H4/Zn (53), 
HCOONH4/Pd/C (54) and N2H4/Raney nickel (55) have been used. The use of catalyst 
such as Pd/C (56) , PtO2 (57), Pd/Al2O3 (58) or Raney nickel (59) in the presence of 
hydrogen gas (H2) is one of the most economical and effective method to carry out 
reduction on a large scale due to lack of side products, and to the recyclability of catalyst. 
However, a major drawback in most of these reactions is lack of selectivity and often the 
reaction stops at an intermediate stage during reduction process. In recent years, there has 
been an increase in the use of metal nanoparticles such as gold nanoparticle being 





Scheme 20. Reduction of aryl-nitro to aryl-amine using different methodologies. 
 
The classical and most frequently used catalyst for the reduction of nitro groups 
are the noble metals such as Pt and Pd supported on activated carbon or alumina (29). Of 
the two metals, Pd is known to be less selective than Pt, but due to its low cost it is most 
used (61). There has been a shift towards the use of in-situ generated hydrogen gas as it 
prevents the use of sophisticated equipment and wastage due to excess gas under 
pressure. Hydrazine hydrate is known to decompose in the presence of trace amounts of 
particular transition metals to H2 and N2 gas (Scheme 14). The in-situ generated H2 gas is 
then adsorbed onto the metal surface to facilitate hydrogenation. The use of hydrazine 
and Pd/C offers many advantages over the classical reducing agents. The reactions are 




can be regenerated and it also avoids aqueous work up and chromatography in most 
cases.     
It has been more than one hundred years since Haber proposed a reaction network 
for the reduction of aryl-nitro and its substituted analogues to aryl-amine. The 
mechanistic scheme (Scheme 21) has been generally accepted through the years (60-62). 
Based on several kinetic studies applying online Raman and IR spectroscopy, only the 
intermediates nitrosoarene, hydroxylamine and aniline product have been detected in 
solution (60). Saha reported that low concentration of nitroso intermediate was present 
and high concentration of hydroxylamine (60), suggesting that the reaction proceeds with 
the fast reduction of nitro to nitroso intermediate that then gets absorbed strongly on the 
metal surface and is reduced quickly to hydroxylamine. The presence of high 
concentration of hydroxylamine in solution is indicative that its reduction to give aniline 
is the rate-determining step, i.e. the slow step. Another proposed route that does exist is 
the formation of azoxy and azo intermediate via condensation. However, the 
condensation only occurs in the presence of a strong base or if the reaction is slow, which 
tends to occur at low temperatures, and results in high amount of hydroxylamine being 





Scheme 21. Proposed reaction network for the reduction of aryl-nitro (60). 
 
Classical adsorption-reaction-desorption mechanisms suggest that the rate of 
catalytic reactions is dependent on two factors: the strength of adsorption and the rate of 
the slow step. In comparison to the other functional groups, the nitro group is known to 
be strongly adsorbed onto the metal surface hence being the first to be reduced. The 
chemoselectivity of other functional groups decreases with the presence of nitro groups 
as they occupy the active sites. The presence of excessive amine can poison the catalyst 
and diminish its catalytic activity (31).  
There are many factors that play a key role in catalytic hydrogenation: substrate, 
type, and size of catalyst, substituents, hydrogen source, temperature, solvent, and 




process. By optimizing the amount and type of catalyst and the hydrogen source, the 
reduction process can be manipulated to achieve maximum efficiency.  
1.4 N,N-Bidentate Imidazopyridine 
Ligands are defined as essentially being either neutral Lewis bases that donates its 
unshared pair (or pairs) of electrons to a transition metal that  has empty valence orbitals  
(Figure 17a ) or as ions that surround the metal ion in a complex (63). The metal and 
ligand form bonds as a result of sharing of electrons between the Lewis acid and the 
Lewis base. The N,N-bidentate ligands have its unshared pair of electrons on the two   
nitrogen atoms (Figure 17b). Compounds such as 2,2‘-bipyridine and 1,10-
phenanthroline are examples of N,N-bidentate ligands (64). They play a key role in 
different areas such as photovoltaics (65), OLED’s (66), molecular sensors (67), DNA 
inetercalation (68) and supramolecular structures (69). The ability of ligands to chelate 
with various metal ions to form resultant complexes enables them to possess a wide range 
of magnetic, photophysical and electrochemical properties. This group has shown that 






Figure 17. (a) Ligand-metal coordinative bond. (b) Examples of N,N-bidentate ligands. 
 
 Imidazopyridines (IMP) over the years have become pharmacologically important 
scaffolds, because they exhibit a broad spectrum of biological and therapeutic activities. 
Some of their therapeutic activities include anti-viral (73), anti-tuberculosis (74), anti-
bacterial and D4 receptor antagonistic properties (75). Recent studies have shown that 
IMP derivatives exhibit potent antitumor activity against breast (76) and pancreatic 
cancer (77). Studies have shown that  enhancing the IMP molecules with metal chelating 
moieties enables IMP to acquire anticancer properties by depleting cancer cells of metal 
ions, needed for their survival and rapid cell division, thus inducing apoptosis (78). The 
N,N-bidentate IMPs (Figure 17b) have recently been shown to exhibit anti-proliferative 





1.5 Prostate Cancer (PC3 cells) 
Cancer remains one of the leading causes of death in the world. According to 
estimates from the International Agency for Research on Cancer (IARC), there were 14.1 
million new cancer cases and 8.2 million deaths worldwide in 2012 alone (81). Cancer is 
a generic term for a large group of diseases that can affect any part of the body: breast, 
pancreas, prostate, liver, lungs, colon, and rectum to name a few. Cancer cells are formed 
when normal cells lose their normal regulatory mechanism that controls growth and cell 
multiplication (82). They become ‘rogue cells’ and often lose the specialized 
characteristic that distinguishes one cell from another, for example a liver cell from blood 
cell (82). Tumors are classified as being benign or malignant. The latter being  more 
dangerous, as they can invade other parts of the body and set-up secondary tumors, a 
process known as metastasis (82). Treatments for cancer include surgery, radiation, 
chemotherapy, hormone therapy, immune therapy, and targeted therapy. 
Prostate cancer (PCa) is the second leading cause of cancer-related death in 
America and most commonly diagnosed (81). PCa growth is often driven by male sex 
hormones called androgen that includes testosterone. Androgen and androgen-receptors 
(AR) play a dual role in the promotion of cell growth and apoptosis (83). A standard 
course of treatment for the metastatic PCa is androgen-deprivation therapy (ADT). It 
lowers the level of androgens in males. However, most patients relapse within one to 
three years and develop castration-resistant (CR) PCa (80, 84, 85). Treatment options 
only prolong survival for few months in CR PCa (86). CR PCa is an incurable disease 




IMPs have recently been investigated as a potent inhibitor by simultaneously 
inhibiting against AR and PI3K/Akt/mTOR signaling pathways, making them promising 
therapeutic agents (79, 80). The Akt signaling pathway promotes cell survival by 
suppressing the androgen-induced apoptosis by phosphorylating and inhibiting the AR 
(83). The inhibition of PI3K/Akt signaling pathway results in cellular growth arrest (80). 
Muniyan in his anti-proliferative study of CR PCa used LNCaP and PC3 cells. LNCaP 
cells are androgen dependent cells and are the indolent form of PCa. They are derived 
from the lymph node metastasis of cancer cells (87). The PC3 cells are androgen 








2.1 General Introduction  
Tetrahydroimidazopyridine (THIP) is a molecule that consists of a five-membered 
imidazole ring, fused with a six-membered heterocyclic piperidine ring. Since it was first 
reported in 1971 (9), there have been different derivatives of THIP synthesized (Figure 
3), and used in a wide array of medicinal and biological applications. It has been used as 
anti-cancer (6-8), anti-inflammatory (9), anti-hypertensive (10), anti-microbial (11, 12), 
and anti-bacterial agents (13). There exist different routes for synthesizing THIP. Of 
which, the catalytic hydrogenation of imidazopyridine (IMP) is the most common route 
used. IMP itself is a highly important pharmacological scaffold. In the catalytic 
hydrogenation process of IMP, the catalysts used are either palladium on carbon (Pd/C) 
or platinum dioxide (PtO2), with hydrogen gas (H2) as hydrogen source. 
The purpose of this dissertation is to synthesize, characterize and evaluate N,N-
bidentate THIP (also referred to as “rIMP” ) as a potential anti-proliferative agent against 




Structure: The THIPs synthesized are novel, in that the N,N-bidentate 5,6,7,8-
tetrahydroimidazo[1,5-a]pyridine has aromatic groups at the 1- and 3-position (Figure 
18). The presence of aromatic rings on either side of the THIP moiety enables it to 
possess fluorophore properties. The presence of pyridine ring at the 1-position and the 
imidazo moiety itself, makes the molecule a N,N-bidentate ligand (Figure 18). 
Method: (a) The method of synthesizing rIMP through the reduction of IMP is unique, in 
that we have used hydrazine as a hydrogen source instead of molecular hydrogen gas 
(Scheme 22a). This replaces the use of pressurized controlled gas and its elaborate 
experimental setup, easy handling of hydrazine hydrate and more importantly being able 
to control the reduction process.  
(b) In the reduction of nitro based IMPs, the optimization of Pd/C and hydrazine hydrate 
can result in single- and double-reduction. In single-reduction, only the nitro group is 
reduced to amine to give srIMPs, and in double-reduction, the nitro group and the double 
bonds in the fused pyridine are reduced to give rIMPs (Scheme 22b). The reaction 
condition used in the double-reduction is then employed to determine scope of reduction 
on various functionalized IMPs.  
Application: Based on the success of the N,N-bidentate imidazo[1,5-a]pyridine in 
treating PCa cells, we tested the viability of novel N,N-bidentate tetrahydroimidazo[1,5-
a]pyridine as a new class of anti-proliferative agent in treating PCa cells. rIMPs were 









Scheme 22. (a) General reaction scheme for synthesizing rIMP. (b) Reaction condition 





2.2 Fortuitous Discovery of Tetrahydroimidazo[1,5-a]pyridine   
The initial purpose of the project included the reduction of nitro based IMPs to 
amino-IMPs. Catalytic hydrogenation using Raney-nickel and tin chloride dihydrate 
(SnCl2-2H2O) were used as catalyst for the reduction of the nitro group. However, 
Raney-nickel was unsuccessful in reducing the nitro-based IMPs, and the use of SnCl2 on 
the other hand, resulted in low yield even with increased reaction time. To increase yield 
and lower reaction time, palladium on carbon (Pd/C) was used along with hydrazine 
hydrate as the hydrogen source. In our first attempt, we used excess Pd/C and hydrazine 
hydrate resulted in the formation of pure white crystals. The NMR results indicated that 
we had successfully reduced the nitro group; however, the presence of strong peaks in the 
aliphatic region indicated that other parts of the molecule were also reduced. Further 
investigation using X-Ray crystallography showed that the fused pyridine ring of the 
imidazopyridine along with the nitro group was reduced resulting in the formation of 
tetrahydroimidazo[1,5-a]pyridine. These results led us into optimizing the reagents, Pd/C 
and hydrazine hydrate, for the single- and double-reduction of nitro-based IMPs and 






RESULTS AND DISCUSSION 
The research objective is to synthesize and characterize novel class of THIP, and 
to expand its application capacity by doing an anti-proliferative study on prostate cancer 
cells. We have developed a two-step procedure in synthesizing N,N-bidentate 
tetrahydroimidazo[1,5-a]pyridine (rIMP). The first-step involves the synthesis of various 
functionalized IMPs that are then subsequently reduced in the second step to give novel 
rIMPs. This chapter covers the synthesis and characterization of IMPs (Section 3.1) and 
rIMPs (Section 3.2), and the study of the anti-proliferative property of these compounds 
against PCa cells using MTS assay (Section 3.3).   
3.1 Synthesis of Substituted N,N-Bidentate Imidazo[1,5-a]pyridine 
Imidazo[1,5-a]pyridines are important pharmacological scaffolds, and have been 
used in medicinal and pharmacological fields (73-77). The synthesis of novel N,N-
bidentate imidazo[1,5-a]pyridine by our group in 2003 (88) has been used and tested as 
an anti-proliferative agent for castration resistant prostate cancer (78-80). Studies 
conducted by Muniyan and Ingersoll have shown that IMP (Figure 19) successfully 
inhibits the AR and PI3K/Akt signaling pathways that results in cellular growth arrest in 





Figure 19. IMPs known to successfully inhibit castration resistant prostate cancer cell. 
 
 For the synthesis of the IMPs in Figure 19, Wang's protocol (20) was employed. It 
is a simple process in which the direct cyclization between the benzaldehyde derivative 
and di-2-pyridil ketone in the presence of ammonium acetate that results in the formation 
of the desired N,N-bidentate IMP (Scheme 23).  
 
Scheme 23. Reaction scheme for the synthesis of N,N-bidentate IMPs (20). 
 
The first-step in the two-step process of synthesizing THIP (Scheme 22), involves 
the synthesis of IMP. This section covers synthesis, results, observation, and 




will be used as precursor for the subsequent single- and double-reduction for the 
synthesis of amine-IMPs and amine-rIMPs. 
3.1.1 Mechanism 
 The plausible reaction mechanism for the formation of imidazo[1,5-a]pyridine 
(Scheme 24) begins with the formation of imine, 67a’, generated by the addition of 
ammonia to the benzaldehyde. The nucleophilic imine attacks the partial positive electron 
deficient carbon of the ketone, the oxygen of the carbonyl in turn picks up a proton from 
the acidic solution to give the intermediate 67b’. The intermediate then undergoes 
subsequent intramolecular reaction to give cyclized intermediate 67d’ at the loss of 
water. The loss of proton results in the formation of the more energetically stable 
aromatic compound, IMP (68).  
 





3.1.2 Result and Discussion 
In the synthesis of IMP, high yields were obtained for most compounds. The yield 
for IMP ranged from 33-95%. Based on the yields obtained of various functionalized 
IMPs, it can be postulated that the electronic- and regio-effect of substituents influences 
the yield of IMP (Table 1).  
Table 1. Yields of Imidazo[1,5-a]pyridine (IMP) 
 
entry 67: Ar in 67 68: yield (%)a 
1 67a: 4-NO2C6H4 68a: 95 
2 67b: 2-NO2C6H4 68b: 78 
3 67c: 3-NO2C6H4 68c: 87 
4 67d: 3-NO2-4-OHC6H3 68d: 65 
5 67e: 3-NO2-4-MeC6H3 68e: 82 
6 67f: 3-NO2-4-OMeC6H3 68f: 66 
7 67g: Ph 68g: 69 
8 67h: 4-BrC6H4 68h: 78 
9 67i: 2-BrC6H4 68i: 71 
10 67j: 3-BrC6H4 68j: 77 
11 67k: 4-ClC6H4 68k: 68
  
12 67l: 4-FC6H4 68l: 80 
13 67m: 4-CNC6H4 68m: 75 
14 67n: 4-SMeC6H4 68n: 33 
15 67o: 4-OEtC6H4 68o: 90 
16 67p: 4-NHAcC6H4 68p: 83 





3.1.2.1  Electronic Effect 
Of the IMP synthesized, the electron donating group (EDG) resulted in lower 
yield compared to the electron withdrawing group (EWG) with the exception of the 
ethoxy (-OEt) substituent, 68o. The nitro group (-NO2) in the para-position, 68a, had the 
highest yield of 95% and the methyl-thiol, 68n, resulted in the lowest yield of 33%. A 
plausible explanation for the difference in yield can be attributed to the electron density at 
the carbon of the carbonyl center in the benzaldehyde moiety, 67, during the imine 
formation of 67a` (Scheme 23). The presence of the EWG in the benzaldehyde lowers the 
electron density at the carbonyl center thus making it more susceptible to be attacked by 
the nucleophilic ammonia to form imine.  
On the other hand, the EDG increases the electron density at the carbonyl center 
making it a poor electrophile thus leading to lower yield. This is evidenced by the yields 
obtained from the electron donating capability of the second substituents in the double-
substituted nitro IMP (68d-f). In decreasing order of electron donating capacity, methyl 
(68e) < < methoxy (68f) < hydroxy (68d); high yield were obtained for methyl (68e, 
82%). The EDG’s, methoxy (68f) and hydroxy (68d) substituents resulted in lower yield 
of 66% and 65% respectively in comparison to the methyl substituent (68e). The methoxy 
and hydroxy groups, though they withdraw electrons in σ bond they donate electrons in 
the conjugated π system. For the nitro group in the meta-position, the yield comparison 
between the mono- (68c) and di-substituted IMP (68d-f) suggests that the mono-
substituted IMP resulted in higher yield in comparison to the di-substituted IMP. This 




3.1.2.2  Regional Effect  
The yield of IMP was also influenced by the position of substituents, as seen 
through the positions of the nitro (68a-c) and bromine (68h-j) substituents. Higher yields 
were observed for substituents that were further away from the aldehyde, due to lack of 
steric hindrances. Higher yields were obtained for the nitro substituent in the order of 
para-(68a, 95%) > meta- (68c, 87%) > ortho-positions (68b, 78%). A similar trend was 
observed for the bromine substituent. Bromine in the para-position (68h) has a higher 
yield of 78% followed by substituent in meta- (68j, 77%) and ortho-position (68i, 71%). 
3.1.3 Structural Determination 
To determine the structure of IMPs (68a-p), 1H and 13C NMR spectra were 
examined. The spectrum of each compound can be seen in Appendices. COSY 2D-NMR 
was also carried out on IMP (68g) to identify proton’s peak position in the molecule 
(Figure 20). The peaks were then compared to the other IMP derivatives. The peaks are 
labeled as italic-alphabets and peak-pattern are designated as singlet ‘(s)’, doublet ‘(d)’, 
triplet ‘(t)’, or multiplet ‘(m)’. 
As seen in Figure 20, there are thirteen aromatic protons present in three different 
rings (X, Y, and Z). The protons g(t), f(d), and d(d) are assigned to ring X, with f and d 
having two equivalent protons due to similar environment. The protons a(d),i(t), j(t), and 
c2(d) are assigned to ring Z with proton a being the most downfield as a result of being 
neighbor to N1 and j being the most up-field. Protons b(d), h(t), e(t), and c1(d) are 




two different rings could possibly experience similar environment resulting in protons at 
similar peak location. The protons c1 and c2 are two-carbon length distance from 
nitrogen, N3 and N1, respectively and are three-carbon length distance from the same 
pyridine nitrogen, N2, experiencing similar shielding and de-shielding effects. 
 
Figure 20. COSY 2D-NMR of IMP 68g. 
 
The peak location and pattern of protons in the rings Y and Z, i.e., protons 
a,b,e,h,i and j with the exception of c1 and c2 are distinct. These peaks are observed in all 




8.90 ppm, a distinct triplet (e) appears in the range δ = 7.70-7.80 ppm and three distinct 
triplets (h, i, j) in the range δ = 6.60-7.20 ppm. However, peaks belonging to the proton c1 
and c2 appear differently, they either overlap perfectly as a doublet (68c, 68g) or as 
different multiplicity, ranging from triplet to multiplet (68d, 68h, 68j, 68n). Otherwise, 
those two protons give two well-resolved doublets, as seen in 68b, 68e, 68f, 68i, 68l, 
68m, and 68p.  
For the IMP with substituent in the para-position in ring X (68a, 68h, 68l, 68m, 
68n, 68p), all have two distinct doublets with two equivalent protons similar to the 
protons seen in Figure 20 (peaks d and f) in the aromatic region. In IMPs with 
substituents in the ortho-position in ring X (68b and 68i), there were two doublets and 
three triplets observed in the aromatic region, characteristic of ortho-substituted 
compounds. For the mono-susbtituted IMPs in the meta-position in ring X (68c, 68j), a 
singlet, a triplet and two doublets were observed, characteristic of meta-substituted 
compounds. For the di-susbtituted IMPs in the meta- and para-positions in ring X (68d, 
68e, 68f), a singlet and two doublets were observed. 
 For the IMPs 68e, 68f, 68n, and 68p, with methyl substituents, proton peaks were 
observed as a singlet at 2.75, 4.06, 2.55, and 2.17 ppm, respectively. The presence of the 
methyl group was further confirmed by 13C NMR for 68e, 68f, 68n, and 68p, with peaks 
observed in the aliphatic region 20.48, 56.83, 15.60, and 24.34 ppm, respectively. The 
hydroxy group in 68d, showed a singlet peak at 10.75 ppm in 1H NMR. The proton on 









3.2 Optimization and Synthesis of N,N-Bidentate Tetrahydroimidazo[1,5-
a]pyridine and Amine based Imidazo[1,5-a]pyridine via Catalytic Hydrogenation 
using Pd/C and Hydrazine Hydrate 
3.2.1 Synthesis and Mechanism 
 In the past couple of decades, tetrahydroimidazopyridines (THIP) have gained 
importance in a wide array of medicinal and biological processes. They have been used 
as anti-cancer (6-8), anti-inflammatory (9), anti-hypertensives (10), anti-microbial (11, 
12), and anti-bacterial agents (13). THIPs are able to carry out activities based on its 
ability to be either agonist or antagonist to key enzymes or receptors in key biological 
processes.  
The N,N-bidentate tetrahydroimidazo[1,5-a]pyridine here on referred to as 
reduced-IMP (rIMP), has a pyridine ring in 1-position. The presence of the lone pairs in 
the nitrogen of THIP-moiety (N2) and the pyridine (N1) gives the molecule the ability to 
chelate with metals, thus enabling it to be a bidentate ligand (Figure 22). Based on the 
success of N,N-bidentate IMP (Figure 19) as an anti-proliferative agent to castration 
resistance prostate cancer, we hope to find similar success with rIMP. 
 




The most commonly used synthetic pathway for the synthesis of THIP, is the 
catalytic hydrogenation of IMP. The methodology employs molecular hydrogen gas at 
high pressure in the presence of the homogeneous catalyst PtO2 (13) or heterogeneous 
catalyst Pd/C (18). In the synthesis of rIMP, we employed the transfer hydrogenation 
process. The novel IMPs (Table 1, 68a-p) synthesized were reduced using hydrazine 
hydrate as hydrogen source and Pd/C as catalyst (Scheme 25a). The mechanistic 
description for the reduction of double bonds in the IMP to synthesize rIMP can be seen 
in Scheme 25b.  
 
Scheme 25. (a) General reaction scheme for the synthesis of rIMP via reduction of IMP. 




The following sections cover the optimization technique employed to carry out 
single- and double-reduction of nitro based IMPs (Table 1, 68a-f) as seen in Scheme 26. 
The condition used in the double-reduction will then be employed in the reduction of 
other functionalized IMPs (Table 1, 68g-p).  
 
Scheme 26. Reaction scheme for the single- and double-reduction of nitro-based IMP to 
give amine-based srIMP and rIMP, respectively.  
 
3.2.2 Single-Reduction  
3.2.2.1  Optimization Condition for Single-Reduction of Nitro Based IMP  
 For the single-reduction of 68a to an amine, tin(II)dichloride dihydrate (SnCl2-
2H2O), Raney-nickel and Pd/C were used as catalyst (Table 2). Pd was successful in the 
reduction of 68a in a short period time (Table 2, run 3). The tin catalyst did not 
completely reduce 68a as starting material was still present (Table 2, run 1). The Raney-
nickel did not reduce 68a at all (Table 2, run 2). It was thus decided to use Pd/C as a 










In the reduction of 68a, the amount of Pd/C and hydrazine hydrate was optimized 
as it can lead to single- or double-reduction (Scheme 25a). In the reduction by Pd/C, the 
nitro group was the first to be reduced because of its ability to be adsorbed to the catalyst 
strongly (89), thus making time a key factor. The synthesis of 69a was monitored using 
thin layer chromatography (TLC). Product 69a was produced efficiently within 1.5 hrs 
(Table 3, run 3-6). A mixture of 69a and 70a was observed when 10 mol% of Pd/C and 




Run catalyst time (hr) yield of 69a (%) 
1 SnCl2-2H2O 24 
a 
2 Raney Ni 24 b 
3 Pd/C 1.5 86 
a Incomplete reaction  




Table 3. Yields of 69a Obtained under Various Ratio 
run ratioa time (hr) yield of 69a (%) 
1 1:10:10 1.5 b 
2 1:10:4 4 78 
3 1:5:3 1.5 85 
4 1:3:3 1.5 86 
5 1:3:4 1.5 81 
6 1:3:5 1.5 83 
7 1:2:3 24 74 
8 1:1:3 48 c 
a 68a(eq): Pd/C (mol %): hydrazine hydrate (eq) 
b side products formed 
c starting material still present 
 
In optimizing the hydrazine hydrate, 78% of 69a was formed when 4 eq were 
used (Table 3, run 2). The yield of 69a increased to 85% as amount of Pd/C was 
decreased to 5 mol% (Table 3, run 3). However, there was no significant difference in 
yield observed when 3-5 mol% of Pd/C and 3-5 eq of hydrazine hydrate were used (Table 
3, run 4-6). The optimal condition was 3 mol% Pd/C and 3 eq hydrazine hydrate, that 
resulted in 86% of 69a being produced. When 2 mol% of Pd/C was used it took 24 hrs 
for the reaction to complete resulting in lower yield of 74% (Table 3, run 7). However, 
the reaction was incomplete when the amount of Pd/C catalyst reduced to 1 mol% after 
running the reaction for 48 hrs (Table 3, run 8). 
 3.2.2.2  Single-Reduction of Various Nitro Based IMP  
The optimized conditions determined for single-reduction were tested on various 
nitro based IMPs (68a-f) (Table 4). For the single-reduction 3 mol% Pd/C and 3 eq 
hydrazine hydrate were used and reaction was monitored via TLC. In the reduction of the 




physically separated due to the unusual sensivity of the amine group. The reactive amine 
group was protected using acetic anhydride and recrystallized, resulting in low yield of 
the stable compound 69b (17%). Higher yields were obtained for mono-substituents (69a 
& c) in comparison to di-substituents (69d-f). In the mono-substituents, the highest yield 
was obtained for the amine group in the para-position (69a, 86%), followed by meta- 
(69c, 79%) and ortho-position (69b, 17%). The more spaced out the nitro group was, the 
more readily it was reduced resulting in high yield. Hence the nitro group in the para-
position (68a) was reduced more readily in comparison to meta- (68c) and ortho-
positions (68b). Although free amine 69b is unstable, other amines such as 69a and 69c 
are quite stable and do not require the protection. 
Table 4. Yields from Single-Reduction of Nitro Based IMP Compounds 
 
Entry 68  R1 R2 R3  69 a R1 R2 R3 time (hr) yield (%) 
1 68a H H NO2  69a H H NH2 1.5 69a: 86 
2 68b NO2 H H  69b NH2 H H 2 69b: 17
b 
3 68c H NO2 H  69c H NH2 H 2 69c: 79 
4 68d H NO2 OH  69d H NH2 OH 4 69d: 68 
5 68e H NO2 Me  69e H NH2 Me 4 69e: 40 
6 68f H NO2 OMe  69f H NH2 OMe 2 69f: 93
c 
a 68(eq): Pd/C (mol%): hydrazine hydrate (eq) (1:3:3) 
b protected amine group using acetic acid anhydride 




The two substituents on the IMP (68d-e) could have an anchoring effect on the 
yield of srIMP (69d-e). The bulky methyl group (-Me) (69e, 40%) resulted in lowest 
yield. The less bulky hydroxy group (-OH) (69d) did result in much higher yield in 
comparison to 69e but this could be due to π-π interaction of the lone pairs of oxygen 
with the Pd/C surface, enhancing the conversion of the nitro group to the amine group 
thus increasing its yield (69d, 68%). The hydroxy group had a positive anchoring effect 
in the reduction. The reduction of 68f resulted in mixture of products 69f and 70f, the 
former being present in high yield as observed by 1H NMR. 
3.2.3 Double-Reduction  
3.2.3.1  Optimization Conditions for Double-Reduction of Nitro Based IMP  
In the double-reduction of 68a to give 70a, the Pd/C, hydrazine hydrate and 
temperature were optimized. The reactions were run for a day and yields were 
determined. To determine the importance of Pd/C and hydrazine hydrate to the reduction, 
reactions were first carried out in the absence of one or the other. Based on the TLC 
analysis, the reaction did not proceed, as only starting material was present. In the 
optimization of temperature, the yield of 70a increased as the temperature increased 
(Table 5, run 1-3). A small non-significant change in yield was observed as the 






In the optimization of hydrazine hydrate, there was no change in the product yield 
(84%) as the amount was reduced from 30 to 15 eq (Table 5, runs 3-4). However, a small 
non-significant change in the yield (83%) was observed as the amount of hydrazine 
hydrate was reduced from 15 to 10 eq (Table 5, runs 4-5).  
Table 5. Yields of 70a Obtained under Various Ratio 
run ratioa Temperature (oC)  yield of 70a (%) 
1 1:15:30 60 72 
2 1:15:30 75 83 
3 1:15:30 90 84 
4 1:15:15 90 84 
5 1:15:10 90 83 
6 1:10:15 90 82 
7 1:20:15 90 80 
a 68a(eq): Pd/C (mol%): hydrazine hydrate (eq) 
 
In the optimization of Pd/C, 15mol % of Pd/C resulted in high yield of 84% 
(Table 5, run 4). As the amount of Pd/C was decreased to 10 mol% (Table 5, run 6) and 
increased to 20 mol% (Table 5, run 7), its yield were decreased to 82% and 80% 
respectively. The best optimization condition for obtaining high yield of 70a was 15 
mol% Pd/C, 15 eq hydrazine hydrate at 90 oC.  
3.2.3.2  Double-reduction of Various Nitro Based IMP 
The optimized condition determined for the double-reduction reaction of 68a was 
tested on various nitro based IMP (68a-f). For the double-reduction reaction 15 mol% 
Pd/C and 15 eq hydrazine hydrate were used and reaction monitored via TLC. The 




were obtained for the mono-substituted in comparison to di-substituted with the 
exception of the methoxy group IMP, 70f. In the double-reduction, the nitro group is the 
first to be reduced then the double bonds of the fused pyridine ring to give the rIMP. 
The reduction was specific to the nitro group and the double bond of fused 
pyridine, as none of the other substituents, hydroxy (70d), alkyl (70e) and ester groups 
(70f) were affected. The highest yield was obtained for the amine group in the para-
position (70a, 84%) followed by meta- (70c, 79%) and ortho-position (70b, 78%). The 
more spaced out the nitro group was, the more readily it was reduced resulting in high 
yield. There was not much difference in yield for the amine group in meta- (70c) and 
ortho-positions (70b). 
Table 6. Yields from Double-Reduction of Nitro Based IMP Compounds 
 
Entry 68  R1 R2 R3  70 a R1 R2 R3 time (hr) yield (%) 
1 68a H H NO2  70a H H NH2 24 70a: 84 
2 68b NO2 H H  70b NH2 H H 24 70b: 78 
3 68c H NO2 H  70c H NH2 H 24 70c: 79 
4 68d H NO2 OH  70d H NH2 OH 18 70d: 72 
5 68e H NO2 Me  70e H NH2 Me 24 70e: 72 
6 68f H NO2 OMe  70f H NH2 OMe 48 70f: 82 




In the reduction of the doubly-substituted derivatives, the hydroxy (70d) and the 
methyl (70e) group at R3 resulted in a similar yield of 72%, whereas the methoxy group 
(70f) resulted in a much higher yield of 82%. In the case of double-substituents, the yield 
seemed to be unaffected by the presence of bulky group as they did not interfere with the 
reduction process of the double bonds. However, the yield of 70f in comparison to single-
substituted nitro group in similar meta-position (70c) suggests that the anchoring 
methoxy group had a positive effect in increasing the yield. The lone pair of electrons in 
the oxygen of the methoxy group shows favorable π-π interaction with the Pd/C that 
could stabilize the molecule in an intermediate step enabling the reduction of double 
bonds of the fused ring. However, when comparing the methoxy to the hydroxy group 
that has similar lone pairs on the oxygen, the bulkiness of the methyl group in 70f could 
prevent the molecule from being adsorbed on the surface of Pd/C for longer period of 
time. The favorable electronic interaction of the lone pairs and the unfavorable steric 
interaction of the bulky methyl group in the methoxy could have enhanced the yield of 
product.  
3.2.3.3  Mechanism for the Double-Reduction of Various Nitro Based IMP 
In the reduction of nitro-IMP, manipulating the reaction conditions can lead to 
single-reduced IMP (srIMP) or double-reduced IMP (rIMP) (Scheme 26). The 
mechanistic description for the synthesis of rIMP via reduction of nitro-IMP can be seen 
in Scheme 27. In the double-reduction process, the nitro group is the first to be reduced to 





Scheme 27. Mechanism for the double-reduction of 68a. Solvents used for TLC analysis 
are ethyl acetate (EA), hexane (H) and ethanol (E). 
 
Whereas the single-reduction is fairly straightforward, all evidence suggests that 
the double-reduction proceeds according to the Scheme 27. The nitro group in the IMP is 
first reduced to amino group to form srIMP. Then, the reduction moves on to take place 
on the six-membered ring to give the final double-reduced product, rIMP. Monitoring the 
reduction of 68a by TLC over time shows the formation of only single-reduced product, 
69a in 1hr. No other product was detected at this stage and the initial reduction takes 
place exclusively at the nitro group, indicating that the nitro group is much easier to be 
reduced and does so first. It is worth mentioning that the molar percentage of Pd/C (3 
mol%) needed for the single-reduction of 68a is much less and so is the amount of 




In the double-reduction reaction, no products have ever been recovered or 
detected in which the nitro group was intact and only the ring reduced. Thus, it is 
reasonable to say that in the double-reduction reaction, hydrazine hydrate is first 
consumed for the reduction of nitro group and then for the ring. The amount of both 
catalyst and hydrazine hydrate was increased to feed these two-processes. In addition, the 
reaction time was also increased to ensure the completion of these two processes.  
3.2.4 Reduction of Functionalized Imidazopyridine Compounds 
The synthesis of rIMPs (70g-p) in Table 7 was carried out by the reduction of 
functionalized IMPs (68g-p) using the optimal condition used in the double-reduction of 
the nitro compounds, 15 mol% Pd/C and 15 eq hydrazine hydrate (Table 5). The rIMPs 
were obtained in good yields, ranging from 46-84%. The lack of specificity of the Pd 
catalyst resulted in the transformation of other functional groups on the IMP as well (61).  
The reduction of 68g resulted in the reduction of double bonds in the fused 
pyridine ring to give the 70g. Reduction of halogenated-IMPs, Br (68h-j) and Cl (68k) 
resulted in products (70h-k) that were all similar to the product obtained for the 
unsubstituted IMP (68g), suggesting that hydrogenolysis resulted in the replacement of 
halogens by a hydrogen (Scheme 18). However, the reduction of fluorine-IMP (68l) 
resulted in product 70l in which the fluorine was not hydrogenolyzed. The strong σ-
bonding between the sp2 carbon and fluorine could possibly prevent the C-F bond from 




Table 7. Yields from Reduction of IMP Compounds 
 
Entry 1: R in 68 70: R in 70a yield of 70 (%) 
1 68g: H 70g: H 70g:  76 
2 68h: 4-Br 70h: H 70h:  65 
3 68i: 2-Br 70i:  H 70i:   73 
4 68j: 3-Br 70j:  H 70j:   84 
5 68k: 4-Cl 70k: H 70k:  46 
6 68l: 4-F 70l:  4-FC6H4 70l:   83 
7 68m: 4-CN 70m: 4-MeC6H4 70m: 81 
8 68n: 4-SMe 70n: 4-SMeC6H4 70n:   -- 
b 
9 68o: 4-OEt 70o: 4-OEtC6H4 70o:  76 
10 68p: 4-NHAc 70p: 4-NHAcC6H4 70p:  72 
a68(eq): Pd/C (mol%): hydrazine hydrate (eq) (1:15:15) 
bno reaction 
 
In the reduction of the nitrile-IMP (68m), it was expected that the nitrile group (-
CN) be reduced to give allylic-amine (-CH2NH2) (34) but instead it was reduced to 
methyl (-CH3) resulting in methyl-rIMP (70m).  
No products were formed when the methyl-thiol IMP (68n) was reduced. This is 
because the presence of sulfur which is a known deactivator of Pd resulted in the 
poisoning of the catalyst (29). The ethoxy-IMP (68o) and acetamide-IMP (68p) when 




functional groups were not affected by the reducing conditions. It is fair to say that the 
carbonyl group is not affected by the reduction conditions used.  
3.2.5 Structural Determination 
 To determine the structure of srIMP and rIMP, 1H and 13C NMR spectra were 
examined, and their spectra can be seen in Appendices. COSY 2D-NMR of rIMP 70g 
was carried out and used to identify proton peak location in the molecule (Figure 23) and 
then compared to other rIMP. X-crystallography of crystal 70a was used to confirm the 
structure of the compound. 
3.2.5.1  Structural Determination of srIMP 
 The 1H NMR of the srIMPs (69a-f) was compared to the 1H NMR of known IMP 
68g (Figure 20). Based on the structural analysis carried out in Section 2.3, similar 
analysis was conducted for the srIMP (69a-e). The distinct protons a,b,e,h,i and j are 
present in the 1H NMR and are characteristic of the fused pyridine ring in imidazo[1,5-
a]pyridine and its neighboring pyridine ring. Two distinct doublets (a, b) appear in the 
range δ = 8.45–8.80 ppm, a single distinct triplet (e) appear in the range δ = 7.70–
7.90 ppm, and three distinct triplets (h, i, j) in the range δ = 6.60–7.10 ppm. The protons 
c1 and c2 appear as two distinct doublets for all compounds. The two protons of the 
primary amine (-NH2) appear as a broad singlet in the range δ = 3.30-5.00 ppm for 
compounds 69a, 69c, 69d, and 69e. In compound 69b, there is a protected acetyl group (-
NHAc) for which the proton in the secondary amine and methyl group shows a peak at 




shows a peak at 9.45 ppm and in 69e the equivalent protons in the methyl group (-CH3) 
shows a peak at 2.24 ppm.   
3.2.5.2  Reduction of Functionalized IMP to give rIMP 
To deduce the structure of rIMP (70a-p), a 2D COSY-NMR was carried out on 
70g and X-Ray crystallography on 70a. Based on the 1H NMR of 70g there are seventeen 
protons in the molecule of which nine are present in the aromatic range (δ = 7.00-8.60 
ppm) and eight in the aliphatic range (δ = 1.80-4.20 ppm). Based on the 2D COSY-NMR 
(Figure 23), protons a(d), g(t), d(t) and b(d) are shown to affect one another and were 
assigned to ring Z. Proton a is the most downfield shifted proton, as it neighbors a 
nitrogen atom. The protons c(2H, d), e(2H, t) and f(m) are shown to affect each other and 
are assigned to ring X. The unsaturated protons h(2H, t), i(2H, t) and j(4H, m) are 
assigned to ring Y. The integration of protons c, e, h and i have two equivalent protons in 
its peaks and the proton j has four equivalent protons in its peak. The equivalent proton 
results from it being in similar environment, i.e., they have same neighbors and 





Figure 23. COSY 2D-NMR of rIMP (70g). 
 
The peak location and splitting of protons in rings Y (a,b,d,g) and Z (h, i, j) are 
distinct characteristic of protons in fused saturated heterocyclic rings and its neighboring 
pyridine ring. The solvent used for NMR of compounds was deuterated DMSO, however, 
for compounds 70l and 70p chloroform-d was used as solvent, resulting in a slight 




(70a-p). In the aromatic regions, two doublets corresponding to protons a and b appear in 
the ranges δ = 8.50-8.60 and 7.90-8.05 ppm, respectively. The proton d appears as a 
triplet in the range δ = 7.70-7.80 ppm and proton g appears as a triple-doublet in the 
range δ = 7.05-7.17 ppm. The triple-doublet for proton g, stems from long range 
coupling. In the aliphatic region three distinct peaks appear. The protons h and j as 
triplets in the range δ = 3.96-4.16 ppm and 3.17-3.35 ppm, respectively. The proton j has 
four protons and appears as a multiplet in the region 1.77-2.00 ppm.   
As stated in discussion, IMPs that had the halogens, bromine (68h-j) and chlorine 
(68k) were hydrogenolyzed to give rIMP compound 70g that had a phenyl ring with no 
substituents in it (Scheme 28). The IMP with the fluorine (68l) was reduced but not 
hydrogenolyzed to give 70l (Scheme 28), as evident by the presence of multiplet fluorine 
peak in 19F-NMR in the range δ -112.72 -112.81 ppm (Figure 24). However, the fluorine 
did couple with the protons in the ring as seen by the triple-doublet at 7.14 ppm and 
multiplet at 7.66 ppm in 1H-NMR. In reality, there was supposed to be two distinct 
doublets that are characteristic of substituent in four-position as seen by the rIMP (70a, 





Scheme 28. Reduction of halogenated-IMP (68h-l). 
 
 




In the nitro based rIMP (70a-f), two protons in primary amine (-NH2) appear as 
broad singlet in the range δ = 4.60-5.90 ppm. For the di-substituted compound 70d the 
hydroxy group (-OH) disappears in the 1H NMR as a result of proton being exchanged 
with the deuterium in the NMR solvent. However, ATR-IR does show a broad peak at the 
3000 cm-1 that is characteristic of O-H vibration absorption. The 1H NMR of methyl 
group in the di-substituted compounds 70e (-Me) and 70f (-OMe) shows the proton 
signals at 2.09 ppm and 3.79 ppm, respectively.  
In the mono-substituted compounds rIMP (70m, 70o, 70p), only the nitrile group 
(-CN) in 68m gets reduced to methyl as seen through the presence of singlet that has 
three equivalent protons at 2.37 ppm in 70m. The analysis by ATR-IR indicates the 
complete reduction of nitrile group to methyl with the absence of absorption for nitrile (-
CN) stretching in 2210-2260 cm-1 and the appearance of primary amine (-NH2) stretching 
in 3300-3500 cm-1. The presence of strong absorption at 2937.39 cm-1 corresponds to 
alkyl (-Me) stretching.  
 






The ethoxy-rIMP (-OEt) (70o) and acetamide-rIMP (-NHAc) (70p) are not 
affected by the reaction conditions. In 70o, a quartet at 4.08 ppm and a triplet at 1.44 ppm 
correspond to the protons at -CH2- and -CH3, respectively. In 70p the proton on 
secondary amine (-NH-) appears at 9.94 ppm and for the methyl group at 2.14 ppm.  
For the X-ray crystallography of 70a (Figure 25), the parameters used for 
deducing the crystal structure and the bond length for the compound can be seen in Table 
8 and Table 9, respectively.  
 








Table 8. Crystal Data and Structure Refinement for 70a 
Empirical formula  C18H18N4 
Formula weight  290.36 
Temperature  100(2) K 
Wavelength  1.54178 Å 
Crystal system  Monoclinic 
Space group  P 21/c 
Unit cell dimensions a = 12.1023(3) Å α= 90°. 
 b = 10.7948(3) Å β= 114.8976(7)°. 
 c = 12.3419(3) Å γ= 90°. 
Volume 1462.52(7) Å3 
Z 4 
Density (calculated) 1.319 Mg/m3 
Absorption coefficient 0.635 mm-1 
F(000) 616 
Crystal size 0.390 x 0.390 x 0.190 mm3 
Theta range for data collection 4.027 to 66.995°. 
Index ranges -14<=h<=14, -12<=k<=12, -13<=l<=14 
Reflections collected 16342 
Independent reflections 2609 [R(int) = 0.0326] 
Completeness to theta = 67.679° 98.5 %  
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 2609 / 0 / 272 
Goodness-of-fit on F2 1.021 
Final R indices [I>2sigma(I)] R1 = 0.0302, wR2 = 0.0727 
R indices (all data) R1 = 0.0313, wR2 = 0.0739 
Extinction coefficient 0.0043(3) 











Table 9. Bond Lengths (Å) for Compound 70a 
Bond Bond length 
       (Å) 
Bond Bond length 
       (Å) 
Bond Bond length 
       (Å) 
N(1)-C(1) 1.3395(15) C(2)-C(3)  1.3879(16) C(12)-C(13)  1.4694(14) 
N(1)-C(5) 1.3517(13) C(3)-C(4)  1.3840(15) C(13)-C(14)  1.3998(15) 
N(2)-C(12) 1.3258(14) C(4)-C(5)  1.3988(15) C(13)-C(18)  1.4009(15) 
N(2)-C(6) 1.3838(13) C(5)-C(6)  1.4648(14) C(14)-C(15)  1.3868(15) 
N(3)-C(12) 1.3736(13) C(6)-C(7)  1.3742(15) C(15)-C(16)  1.3978(16) 
N(3)-C(7) 1.3756(13) C(7)-C(8)  1.4992(14) C(16)-C(17)  1.4020(15) 
N(3)-C(11) 1.4712(14) C(8)-C(9)  1.5273(16) C(17)-C(18)  1.3799(15) 
N(4)-C(16) 1.3824(14) C(9)-C(10)  1.5246(17)   
C(1)-C(2) 1.3810(16) C(10)-C(11)  1.5239(15)   
 
In the X-ray crystallography of 70a (Figure 25), the saturated six-membered 
heterocyclic ring (N3C7C8C9C10C11) is fused to the imidazo ring (N2N3C6C7C12) at 
N3 and C7 atoms. The saturated ring is no longer coplanar with the imidazo as observed 
in imidazo[1,5-a]pyridine but adopts a half-chair conformation (Figure 26). This is 
achieved because the N3-C7 bond is also in the rigid planar ring of the imidazole. The 
pyridine ring attached to C6 of the imidazole is twisted to each other at a dihedral angle 
of 12.80° between the planes C1C2C3C4C5N1 and N2N3C6C7C12, respectively. 
Similarly, the amine-benzyl ring attached to the imidazo at C12 is twisted at a greater 
angle to each other as is evident from the dihedral angle of 36.67° between planes of 






Figure 26. The half-chair conformation observed in the six-membered ring that is fused 
into imidazole. Color scheme for different rings is used to better visualize each ring. 
Green color: for four aliphatic C’s; Yellow color: for pyridine ring at 1-position; Pink 
color: for 4-aminophenyl at 1-position. Imidazole ring is depicted in blue (nitrogen atom) 
and white (carbon) colors. Top left: front view from side of imidazole; Top right: front 
view from side of the six-membered ring; Bottom left: front view from pyridine side; and 
Bottom right: top view. The half-chair conformation can be clearly observed in these 
different viewpoints. 
 
The X-ray crystallography also revealed that there were H-bondings being formed 
between imidazole and 4-aminophenyl. Since the amine group (N4) provides H, which is 
an acceptor, the nitrogen (N2) in imidazole becomes a donor (Figure 27a). The distance 
between them (~ 3.06 Å, Figure 27b) indicates that there is a strong H-bonding 
interaction. Interestingly, there is no H-bonding between the amine group and pyridine (at 
the 1-position) even though there is a nitrogen atom (N1) available as a potential donor. 







Figure 27. (a) Hydrogen bonding is observed between imidazole and 4-aminophenyl at 
the 3-position. The color scheme is the same as in Figure 26 (above). (b) The distance 
between two N’s is depicted. 
 
In addition, the X-Ray crystallography also revealed the presence of π-π stacking 
interaction as seen through short distances between the aromatic rings. A partial 
overlapping of two intermolecular rings occurs between imidazole and phenyl (at the 3-
position). As shown in Figure 28, the C7 of imidazole in one molecule and the C15 of 
phenyl in the other molecules are at a distance of 3.382 Å. Again, the C12 in the same 






each molecule has an imidazole ring and a phenyl ring, there are two partial overlapping 
areas and the π-π interaction takes hold in these two molecules which are in arranged in 
C2 symmetry. Multiple sites reinforce the strong π-π stacking between these two 
molecules.  
 
Figure 28. The π-π stacking interaction observed between the imidazole of one molecule 
and phenyl of the other molecule. It is also found between pyridine and imidazole. 
 
Furthermore, the pyridine moiety in each molecule is also found to have the π-π 
stacking interaction with the imidazole ring. As depicted in Figure 29, the distance 
between C2 of pyridine and C6 of imidazole is 3.276 Å, and the distance between C2 (of 
pyridine) and C7 (of imidazole) 3.236 Å. While this happens between molecules a and c, 
the other side of the same imidazole ring in molecule a still has the stacking interaction 




other words, one molecule (molecule a, for instance) is bridging two other molecules 
(molecules b and c) through the imidazole ring. This kind of interaction forms a chain 
along which molecules are stacked. The direction of stacking is different from the 
direction of chain resulting from the intermolecular H-bonding (Figure 30). 
 
Figure 29. Illustration of π-π stacking interaction between molecules. The imidazole 
moiety has the stacking interaction on both sides. One is with phenyl and the other with 
pyridine. Molecules c and d are omitted except pyridine moieties to show the relationship 
with the imidazole ring. 
 









Figure 30. Different direction of chains formed from stacking (vertical, multi-colored) 




3.3 Biological Study of Anti-Proliferative Property of IMP and rIMP against 
Prostate Cancer Cell Lines 
Prostate cancer (PCa) is the second leading cause of cancer-related deaths in 
America and the most commonly diagnosed (81). Amongst men, PCa growth is often 
driven by male sex hormones such as androgen including testosterone. Androgen and 
androgen-receptors (AR) play a dual role in the promotion of cell growth and apoptosis 
(83). A standard course of treatment for metastatic PCa is androgen-deprivation therapy 
(ADT). ADT lowers the level of androgens in males. However, treatments have been 
shown to only prolong survival for a few months. Other treatments have been shown 
much more effective for early stage PCa.  
IMPs have recently been investigated as a potent inhibitor by simultaneously 
inhibiting AR and PI3K/Akt/mTOR signaling pathways in PC3 cell lines, making them 
promising therapeutic agents (79, 80). The inhibition of the PI3K/Akt signaling pathway 
results in cellular growth arrest (80). The PC3 cells are androgen independent cells and 
are the aggressive metastatic form of CR PCa cell lines. They are derived from bone 
metastases (87). The DU145 PCa cells are also androgen independent cells, however, 
they are the moderate metastatic form of CR PCa cell lines derived from the central 
nervous system metastases (90).  
To investigate the potential inhibitory activity in CR PCa cancer cells, PC3 and 
DU145 cells, novel IMPs and rIMPs (Figure 31) have been used in a preliminary dose 
dependent anti-proliferative study. The IMP is synthesized using the protocol from our 




synthesized and then reduced using our method of transfer hydrogenation. For the 
synthesis of IMP-4NH2 the precursor IMP-4NO2 is first synthesized and then reduced 
using the single-reduction protocol. 
 
Figure 31. The derivatives of imidazo[1,5-a]pyridine and tetrahydroimidazo[1,5-
a]pyridine. 
 
To determine the anti-proliferative effect of IMP and rIMP derivatives, a cell-
proliferation assay was initially performed on PC3 and DU145 PCa cells. After 72 hrs 




2NH2, rIMP-3NH2 and rIMP-4Me reduced cell proliferation by an average of 44%, 32%, 
66%, 77%, 68%, and 55%, respectively. As seen below in Figure 32a, the rIMP 
derivatives are more potent in inhibiting the cell proliferation of PC3 PCa cells than the 
IMP derivatives, especially when comparing the activity of IMP-4NH2 with rIMP-4NH2, 
with the latter showing more than twice the potency. When comparing the structures 
between IMP and rIMP (Figure 31), both are very similar, however, the difference being 
the presence of saturated six-membered fused ring in rIMP. The saturated ring in rIMP 
results in a bent structure (Figure 25) as opposed to planar structure in IMP, which could 
possibly contribute to its inhibition activity. When comparing the functional groups on 
the phenyl ring, the amine group (-NH2) was more potent compared to the alkyl (-Me) 
and hydroxy (-OH) groups. Of the amine-rIMP, the presence of amine at the ortho-
position had most potency of 77% compared to the meta- and para-position. Further 
work is needed to be conducted such as immunoblot assays on the treated PC3 PCa cell 
to determine the drug target pathway, it can be speculated that the active site of the 
inhibited protein has a hydrophobic pocket and shows greater inhibition to the amine 
group in the ortho-position of the phenyl ring.  
 The dose-dependent effect of rIMP-4NH2, rIMP-2NH2, and rIMP-3NH2 on PC3 
cells was also examined. Upon treatment with 0-100 μM rIMP for 72 hrs, cell growth 
was measured. In regular culture media, all the rIMP derivatives inhibited PC3 cell 






Figure 32. (a) Effects of 10 μM IMP and rIMP derivatives on PC3 cell proliferation in 
regular culture condition. (b) Dose-dependent effect of rIMP derivatives on PC3 cell lines 





























































In treating DU145 PCa cells with 10 μM of IMP-2OH, rIMP-4Me and rIMP-
2NH2, only IMP-2OH reduced cell proliferation by an average of 38%. As seen in Figure 
33, the IMP derivative was more potent at inhibiting the cell proliferation of DU145 PCa 
cells than the rIMP derivatives. The rIMP derivatives were shown to be highly ineffective 
in treating DU145PCa cells using this protocol. 
 
Figure 33. Effects of 10 μM IMP and rIMP derivatives on DU145 cell proliferation in 




































4.1 General Aspects 
All the reactions were carried out in a nitrogen atmosphere. All the chemicals 
were used as received. Palladium on activated carbon (10%) from Aldrich was used as 
the catalyst. Melting points were obtained in open capillary tubes with Barnstead 
Electrothermal Mel-Temp 1201D melting point apparatus and are uncorrected. 1H NMR 
(500 MHz), and 13C NMR (126 MHz) spectra were recorded with TMS as an internal 
standard, and 19F NMR (471 MHz) spectra were recorded with 4-fluorobenzaldehyde as a 
reference on Bruker Ultrashield 500 plus. Infrared (IR) Spectra were run on either 
PerkinElmer Spectrum 65 FT-IR spectrometer in KBR pellets or on Bruker Alpha FT-IR 
spectrometer in solid state. Analytical thin-layer chromatography (TLC) was carried out 
using Sorbent Technologies pre-coated silica or alumina neutral gel plates with UV 254 
indicator. The TLC plates were visualized using Spectroline Longlife Filter with short 
(254 nm) and long (365 nm) UV wavelength. X-ray Crystallography was performed by 
the X-ray Crystallography Center at the College of William and Mary, Williamsburg 
Virginia. For the MTS assay Promega CellTiter 96® AQueous One Solution Reagent was 




4.2 General Procedure for the Synthesis of Imidazo[1,5-a]pyridine  
To a 100 ml flask equipped with magnetic stirrer, nitrogen inlet and reflux 
condenser, a mixture di-2-pyridil ketone (5 mmol), substituted benzaldehyde (10 mmol), 
ammonium acetate (25 mmol) and 50 ml glacial acetic-acid were added and refluxed 
under nitrogen at 110 oC for 5 hrs. After 5 hrs the reaction mixture was cooled to room 
temperature and poured into a beaker of 200 ml cold water. The precipitate that formed 
was vacuum filtered, dried and recrystallized with the appropriate solvent. If no solid was 
formed, the mixture was neutralized using base, either sodium hydroxide (NaOH) or 
sodium cabonate (NaHCO3). If no solid formed after neutralization the mixture was 
extracted with methylene chloride (CH2Cl2) and washed with brine and then water. The 
organic layer was then separated and dried over sodium sulfate (Na2SO4). The solvent 
was removed under reduced pressure, and the residue was recrystallized to afford pure 
compound. 
3-(4-nitrophenyl)-1-(pyridin-2-yl)imidazo[1,5-a]pyridine (68a): Recrystallization 
(ethyl acetate/ethanol) afforded compound 68a (95 %) as a red crystal. mp 237-239 °C; 
1H NMR (500 MHz, CDCl3) δ 8.82 (d, J = 9.2 Hz, 1H), 8.66 (ddd, J = 4.8, 1.7, 0.8 Hz, 
1H), 8.41 (d, J = 8.9 Hz, 2H), 8.38 (d, J = 7.2 Hz, 1H), 8.26 (d, J = 8.0 Hz, 1H), 8.11 (d, 
J = 8.9 Hz, 2H), 7.76 (td, J = 7.8, 1.8 Hz, 1H), 7.16 (ddd, J = 7.4, 4.9, 1.1 Hz, 1H), 7.04 
(ddd, J = 9.2, 6.4, 0.8 Hz, 1H), 6.84 – 6.79 (m, 1H). 13C NMR (126 MHz, CDCl3) δ 
154.47, 149.11, 147.18, 136.41, 136.33, 135.45, 132.20, 131.40, 128.21, 124.42, 122.38, 





(ethanol) afforded compound 68b (62 %) as a red solid. mp 163-165 °C; 1H NMR (500 
MHz, CDCl3) δ 8.75 (d, J = 9.2 Hz, 1H), 8.63 (dd, J = 4.8, 0.8 Hz, 1H), 8.22 (d, J = 8.2 
Hz, 1H), 8.15 (d, J = 8.0 Hz, 1H), 7.81 (d, J = 0.6 Hz, 1H), 7.80 – 7.79 (m, 1H), 7.73 – 
7.67 (m, 2H), 7.60 (d, J = 7.1 Hz, 1H), 7.10 (ddd, J = 7.4, 4.9, 1.0 Hz, 1H), 6.99 (ddd, J = 
9.2, 6.4, 0.6 Hz, 1H), 6.67 (t, J = 6.3 Hz, 1H). 13C NMR (126 MHz, CDCl3) δ 154.72, 
149.01, 148.71, 136.28, 133.62, 133.32, 133.22, 130.99, 130.50, 130.21, 125.14, 124.92, 
121.91, 121.52, 121.11, 120.66, 119.93, 114.39. 
3-(3-nitrophenyl)-1-(pyridin-2-yl)imidazo[1,5-a]pyridine (68c): Recrystallization 
(ethyl acetate/ ethanol) afforded compound 68c (67 %) as an orange solid. mp 191-194 
°C; 1H NMR (500 MHz, CDCl3) δ 8.79 (dt, J = 9.2, 1.2 Hz, 1H), 8.76 (t, J = 1.9 Hz, 1H), 
8.65 (ddd, J = 4.8, 1.8, 0.9 Hz, 1H), 8.30 (dddd, J = 7.5, 6.4, 2.2, 1.0 Hz, 2H), 8.26 – 8.23 
(m, 2H), 7.77 (d, J = 1.8 Hz, 1H), 7.74 (d, J = 8.3 Hz, 1H), 7.72 (s, 1H), 7.14 (ddd, J = 
7.4, 4.9, 1.2 Hz, 1H), 7.01 (ddd, J = 9.2, 6.4, 0.9 Hz, 1H), 6.78 (ddd, J = 7.6, 6.5, 1.3 Hz, 
1H). 13C NMR (126 MHz, CDCl3) δ 154.57, 149.08, 148.72, 136.37, 135.23, 133.80, 
131.92, 131.54, 130.90, 130.15, 123.18, 122.59, 122.24, 121.64, 121.03, 120.90, 120.00, 
115.02. 
2-nitro-4-(1-(pyridin-2-yl)imidazo[1,5-a]pyridin-3-yl)phenol (68d): Recrystallization 
(ethanol) afforded compound 68d (65%) as a purple solid. mp 244-245 °C; 1H NMR (500 
MHz, CDCl3) δ 10.74 (s, 1H), 8.75 (dt, J = 9.2, 1.2 Hz, 1H), 8.64 (ddd, J = 4.8, 1.7, 0.9 




7.74 (td, J = 7.9, 1.8 Hz, 1H), 7.37 (t, J = 8.6 Hz, 1H), 7.13 (ddd, J = 7.4, 4.9, 1.1 Hz, 
1H), 6.98 (ddd, J = 9.2, 6.4, 0.8 Hz, 1H), 6.78 – 6.72 (m, 1H). 13C NMR (126 MHz, 
CDCl3) δ 155.17, 154.65, 149.10, 143.07, 137.52, 136.38, 135.11, 133.66, 131.09, 
130.52, 123.96, 123.05, 122.19, 121.35, 121.04, 120.97, 120.81, 119.94, 114.82. 
3-(4-methyl-3-nitrophenyl)-1-(pyridin-2-yl)imidazo[1,5-a]pyridine (68e): 
Recrystallization (ethanol) afforded compound 68e (82%) as an orange solid. mp 220-222 
°C; 1H NMR (500 MHz, CDCl3) δ 8.76 (d, J = 9.2 Hz, 1H), 8.64 (dd, J = 4.8, 0.6 Hz, 
1H), 8.49 (d, J = 1.8 Hz, 1H), 8.26 (d, J = 7.2 Hz, 1H), 8.23 (d, J = 8.0 Hz, 1H), 8.03 (dd, 
J = 7.9, 1.8 Hz, 1H), 7.74 (td, J = 7.5, 1.5 Hz, 1H), 7.52 (d, J = 8.0 Hz, 1H), 7.13 (ddd, J 
= 7.4, 4.9, 1.0 Hz, 1H), 6.98 (dd, J = 9.2, 6.4 Hz, 1H), 6.78 – 6.73 (m, 1H), 2.70 (s, 3H). 
13C NMR (126 MHz, CDCl3) δ 154.65, 149.56, 149.06, 136.35, 135.32, 133.80, 133.60, 
132.25, 131.27, 130.69, 129.45, 123.80, 122.15, 121.47, 121.10, 120.80, 119.97, 114.82, 
20.46. 
3-(4-methoxy-3-nitrophenyl)-1-(pyridin-2-yl)imidazo[1,5-a]pyridine (68f): 
Recrystallization (ethyl acetate/ethanol) afforded compound 68f (66 %) as an orange 
crystal. mp 226-228 °C; 1H NMR (500 MHz, DMSO) δ 8.68 (d, J = 9.2 Hz, 1H), 8.61 (d, 
J = 4.4 Hz, 1H), 8.46 (d, J = 7.2 Hz, 1H), 8.34 (d, J = 2.2 Hz, 1H), 8.17 (dt, J = 5.9, 3.1 
Hz, 2H), 7.79 (tt, J = 5.5, 2.7 Hz, 1H), 7.52 (d, J = 8.8 Hz, 1H), 7.18 (ddd, J = 7.3, 4.9, 
0.9 Hz, 1H), 7.06 (dd, J = 9.2, 6.3 Hz, 1H), 6.89 – 6.85 (m, 1H), 4.06 (s, 3H). 13C NMR 
(126 MHz, DMSO) δ 154.37, 152.25, 148.88, 139.53, 136.30, 135.17, 133.51, 129.99, 




3-phenyl-1-(pyridin-2-yl)imidazo[1,5-a]pyridine (68g): Recrystallization (ethyl 
acetate/hexane) afforded compound 68g (69%) as a yellow solid. mp 92-93 °C; 1H NMR 
(500 MHz, CDCl3) δ 8.71 (d, J = 9.2 Hz, 1H), 8.63 (d, J = 4.4 Hz, 1H), 8.28 – 8.22 (m, 
2H), 7.84 (d, J = 7.7 Hz, 2H), 7.72 (t, J = 7.7 Hz, 1H), 7.55 (t, J = 7.1 Hz, 2H), 7.47 (t, J 
= 7.2 Hz, 1H), 7.13 – 7.06 (m, 1H), 6.96 – 6.88 (m, 1H), 6.65 (t, J = 6.7 Hz, 1H). 13C 
NMR (126 MHz, CDCl3) δ 155.08, 149.01, 138.09, 136.25, 130.61, 130.23, 130.16, 
129.08, 128.95, 128.42, 121.87, 121.62, 121.05, 120.47, 119.96, 113.93. 
3-(4-bromophenyl)-1-(pyridin-2-yl)imidazo[1,5-a]pyridine (68h): Recrystallization 
(ethanol) afforded compound 68h (78%) as a yellow crystal. mp 155-157 °C; 1H NMR 
(500 MHz, CDCl3) δ 8.73 – 8.70 (m, 1H), 8.65 – 8.61 (m, 1H), 8.24 – 8.20 (m, 2H), 7.76 
– 7.66 (m, 5H), 7.11 (ddd, J = 7.3, 4.8, 1.0 Hz, 1H), 6.97 – 6.92 (m, 1H), 6.71 – 6.66 (m, 
1H). 13C NMR (126 MHz, CDCl3) δ 154.84, 149.02, 136.86, 136.31, 132.27 , 130.89 , 
130.42 , 129.76 , 129.08 , 122.95 , 121.99 , 121.36 , 121.20 , 120.62 , 119.93 , 114.30. 
3-(2-bromophenyl)-1-(pyridin-2-yl)imidazo[1,5-a]pyridine (68i): Recrystallization 
(ethanol) afforded compound 68i (71%) as a yellow crystal. mp 200-203 °C; 1H NMR 
(500 MHz, CDCl3) δ 8.73 (dt, J = 9.3, 1.1 Hz, 1H), 8.64 (ddd, J = 4.9, 1.8, 0.9 Hz, 1H), 
8.22 (dt, J = 8.1, 1.0 Hz, 1H), 7.75 (dd, J = 8.0, 1.1 Hz, 1H), 7.73 – 7.68 (m, 1H), 7.63 
(dd, J = 7.6, 1.7 Hz, 1H), 7.61 (dt, J = 7.2, 1.1 Hz, 1H), 7.49 (tt, J = 7.4, 3.7 Hz, 1H), 
7.42 – 7.36 (m, 1H), 7.10 (ddd, J = 7.4, 4.9, 1.2 Hz, 1H), 6.98 (ddd, J = 9.2, 6.4, 0.9 Hz, 




136.26 , 133.55 , 133.19 , 131.36 , 131.20 , 130.11 , 129.60 , 127.83 , 124.42 , 122.35 , 
121.55 , 121.27 , 120.47 , 119.92. 
3-(3-bromophenyl)-1-(pyridin-2-yl)imidazo[1,5-a]pyridine (68j): Recrystallization 
(ethanol) afforded compound 68j (77%) as a yellow solid. mp 152-154 °C; 1H NMR (500 
MHz, CDCl3) δ 8.73 (dt, J = 9.2, 1.2 Hz, 1H), 8.63 (ddd, J = 4.8, 1.8, 0.9 Hz, 1H), 8.27 – 
8.22 (m, 2H), 8.03 (t, J = 1.7 Hz, 1H), 7.78 (ddd, J = 7.7, 1.6, 1.0 Hz, 1H), 7.73 (ddd, J = 
8.0, 7.5, 1.8 Hz, 1H), 7.59 (ddd, J = 8.0, 1.9, 1.0 Hz, 1H), 7.41 (t, J = 7.9 Hz, 1H), 7.11 
(ddd, J = 7.4, 4.9, 1.2 Hz, 1H), 6.95 (ddd, J = 9.2, 6.4, 0.9 Hz, 1H), 6.73 – 6.67 (m, 1H). 
13C NMR (126 MHz, CDCl3) δ 154.80 , 149.02 , 136.31 , 132.12 , 131.80 , 131.25 , 
130.96 , 130.50 , 126.58 , 123.18 , 121.98 , 121.37 , 121.31 , 120.66 , 119.96 , 114.39. 
3-(4-chlorophenyl)-1-(pyridin-2-yl)imidazo[1,5-a]pyridine (68k): Recrystallization 
(ethanol) afforded compound 68k (68%) as a yellow solid. mp 149-151 °C; 1H NMR 
(500 MHz, CDCl3) δ 8.71 (dt, J = 9.2, 1.1 Hz, 1H), 8.63 (ddd, J = 4.8, 1.7, 0.9 Hz, 1H), 
8.22 (d, J = 8.0 Hz, 1H), 8.20 (d, J = 7.2 Hz, 1H), 7.79 (d, J = 8.5 Hz, 2H), 7.72 (td, J = 
7.9, 1.8 Hz, 1H), 7.52 (d, J = 8.5 Hz, 2H), 7.10 (ddd, J = 7.4, 4.9, 1.1 Hz, 1H), 6.93 (ddd, 
J = 9.2, 6.4, 0.9 Hz, 1H), 6.70 – 6.64 (m, 1H). 
3-(4-fluorophenyl)-1-(pyridin-2-yl)imidazo[1,5-a]pyridine (68l): Recrystallization 
(ethanol/water) afforded compound 68l (80%) as a yellow crystal. mp 133-135 °C; 1H 
NMR (500 MHz, CDCl3) δ 8.71 (d, J = 9.2 Hz, 1H), 8.63 (d, J = 4.5 Hz, 1H), 8.22 (d, J = 
8.0 Hz, 1H), 8.17 (d, J = 7.2 Hz, 1H), 7.85 – 7.77 (m, 2H), 7.72 (t, J = 7.7 Hz, 1H), 7.28 




NMR (126 MHz, CDCl3) δ 163.99 , 162.01 , 154.82 , 148.93 , 137.12 , 136.37 , 130.39 , 
130.33 , 130.18 , 126.30 , 121.87 , 121.34 , 121.12 , 120.54 , 119.93 , 116.30 , 116.13 , 
114.13 . 19F NMR (471 MHz, CDCl3) δ -111.49 – -111.57 (m). 
4-(1-(pyridin-2-yl)imidazo[1,5-a]pyridin-3-yl)benzonitrile (68m): Recrystallization 
(ethanol/acetonitrile) afforded compound 68m (75%) as a yellow solid. mp 214-215 °C; 
1H NMR (500 MHz, CDCl3) δ 8.77 (d, J = 9.2 Hz, 1H), 8.65 – 8.61 (m, 1H), 8.30 (d, J = 
7.2 Hz, 1H), 8.23 (d, J = 8.0 Hz, 1H), 8.01 (d, J = 8.4 Hz, 2H), 7.81 (d, J = 8.4 Hz, 2H), 
7.74 (td, J = 7.8, 1.8 Hz, 1H), 7.13 (ddd, J = 7.4, 4.9, 1.0 Hz, 1H), 7.03 – 6.97 (m, 1H), 
6.77 – 6.73 (m, 1H).. 13C NMR (126 MHz, CDCl3) δ 154.51 , 149.07 , 136.37 , 135.71 , 
134.46 , 132.79 , 131.80 , 131.11 , 128.18 , 122.24 , 121.80 , 121.28 , 120.94 , 119.99 , 
118.63 , 114.98 , 111.72. 
3-(4-(methylthio)phenyl)-1-(pyridin-2-yl)imidazo[1,5-a]pyridine (68n): 
Recrystallization (ethanol) afforded compound 68n (33%) as a yellow crystal. mp 146-
147 °C; 1H NMR (500 MHz, CDCl3) δ 8.71 (d, J = 9.2 Hz, 1H), 8.62 (dd, J = 13.1, 8.9 
Hz, 1H), 8.27 – 8.17 (m, 2H), 7.76 (d, J = 8.3 Hz, 2H), 7.72 (dd, J = 10.8, 4.6 Hz, 1H), 
7.41 (d, J = 8.3 Hz, 2H), 7.13 – 7.07 (m, 1H), 6.92 (dd, J = 8.7, 6.9 Hz, 1H), 6.65 (t, J = 
6.8 Hz, 1H), 2.55 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 154.84 , 148.85 , 139.85 , 
137.72 , 136.38 , 130.40 , 130.25 , 128.62 , 126.63 , 126.59 , 121.84 , 121.60 , 121.10 , 





3-(4-ethoxyphenyl)-1-(pyridin-2-yl)imidazo[1,5-a]pyridine (68o): Recrystallization 
(ethanol/water) afforded compound 68o (90%) as a solid. mp 133-135 °C; 1H NMR (500 
MHz, CDCl3) δ 8.68 (d, J = 9.2 Hz, 1H), 8.62 (d, J = 4.2 Hz, 1H), 8.23 (d, J = 8.0 Hz, 
1H), 8.18 (d, J = 7.2 Hz, 1H), 7.74 (d, J = 8.1 Hz, 2H), 7.71 (t, J = 7.8 Hz, 1H), 7.09 (t, J 
= 6.1 Hz, 1H), 7.06 (d, J = 8.7 Hz, 2H), 6.90 (t, 1H), 6.62 (t, J = 6.7 Hz, 1H), 4.12 (q, J = 
6.9 Hz, 2H), 1.47 (t, J = 6.9 Hz, 3H).13C NMR (126 MHz, CDCl3) δ 159.56, 155.11, 
148.95, 138.21, 136.26, 130.19, 129.95, 129.87, 122.39, 121.78, 121.64, 120.81, 120.34, 
119.94, 115.06, 113.70, 63.66, 14.80. 
N-(4-(1-(pyridin-2-yl)imidazo[1,5-a]pyridin-3-yl)phenyl)acetamide (68p): 
Recrystallization (ethanol) afforded compound 68 (83%) as a yellow solid. mp 236-238 
°C; 1H NMR (500 MHz, DMSO) δ 9.95 (s, 1H), 8.64 (d, J = 9.1 Hz, 1H), 8.59 (d, J = 4.0 
Hz, 1H), 8.30 (d, J = 7.0 Hz, 1H), 8.18 (d, J = 8.0 Hz, 1H), 7.79 (dd, J = 31.1, 8.2 Hz, 
5H), 7.72 (d, J = 6.2 Hz, 1H), 7.13 – 7.10 (t, 1H), 6.99 – 6.91 (t, 1H), 6.72 (t, J = 6.7 Hz, 
1H), 2.17 (s, 3H). 13C NMR (126 MHz, DMSO) δ 169.41, 154.92, 149.01, 139.93, 
137.91, 136.35, 130.01, 129.96, 128.71, 124.67, 121.93, 121.53, 121.32, 120.51, 119.95, 
119.72, 114.15, 24.34. 
4.3 Single-Reduction of Nitro-Imidazopyridine 
To a 50 ml two-neck flask equipped with a magnetic stirrer and condenser under 
nitrogen was added IMP (0.5 mmol), Pd/C and ethanol (10 ml). After running reaction at 
90 oC for five minutes, hydrazine hydrate was added drop-wise. Reaction was monitored 




to half volume. If no precipitate was formed on cooling, water was added to form 
precipitate. The precipitate was filtered and dried under UV Lamp.  
4-(1-(pyridin-2-yl)imidazo[1,5-a]pyridin-3-yl)aniline (69a): Recrystallization (ethanol) 
afforded compound 69a (86%) as a yellow crystal. mp 220-222 °C; 1H NMR (500 MHz, 
CDCl3) δ 8.66 (dt, J = 9.2, 1.1 Hz, 1H), 8.62 (ddd, J = 4.8, 1.8, 0.9 Hz, 1H), 8.23 (dt, J = 
8.1, 0.9 Hz, 1H), 8.17 (dd, J = 6.3, 0.9 Hz, 1H), 7.73 – 7.67 (m, 1H), 7.63 – 7.58 (m, 2H), 
7.07 (ddd, J = 7.4, 4.9, 1.1 Hz, 1H), 6.87 (ddd, J = 9.2, 6.3, 0.8 Hz, 1H), 6.84 – 6.79 (m, 
2H), 6.60 (ddd, J = 7.4, 6.5, 1.2 Hz, 1H), 4.29 – 3.05 (s, 2H). 13C NMR (126 MHz, 
CDCl3) δ 155.17, 148.91, 147.23, 138.72, 136.22, 129.93, 129.80, 129.76, 121.79, 
121.71, 120.67, 120.23, 120.04, 119.92, 115.21, 113.48. 
N-(2-(1-(pyridin-2-yl)imidazo[1,5-a]pyridin-3-yl)phenyl)acetamide (69b): Extraction 
resulted in liquid. The amine is protected using acetic anhydride in ethyl acetate and then 
recrystallized (acetone/hexane). Recrystallization afforded compound 69b (86%) as a 
yellow solid. mp 195-196 °C; 1H NMR (500 MHz, CDCl3) δ 10.77 (s, 1H), 8.77 (d, J = 
9.2 Hz, 1H), 8.66 (d, J = 4.7 Hz, 1H), 8.59 (d, J = 8.3 Hz, 1H), 8.32 (d, J = 7.2 Hz, 1H), 
8.16 (d, J = 8.0 Hz, 1H), 7.75 (td, J = 7.9, 1.6 Hz, 1H), 7.68 (d, J = 7.7 Hz, 1H), 7.46 (t, J 
= 7.5 Hz, 1H), 7.24 (t, J = 7.6 Hz, 1H), 7.14 (dd, J = 6.8, 5.4 Hz, 1H), 7.00 (dd, J = 9.2, 
6.4 Hz, 1H), 6.72 (t, J = 6.8 Hz, 1H), 2.15 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 
168.46, 154.50, 149.25, 136.76, 136.47, 134.73, 129.93, 129.92, 129.80, 126.97, 123.26, 




3-(1-(pyridin-2-yl)imidazo[1,5-a]pyridin-3-yl)aniline (69c): Extraction resulted in 
liquid that overtime afforded compound 69c (79%) as orange crystal. mp 165-166 °C; 1H 
NMR (500 MHz, CDCl3) δ 8.69 (dt, J = 9.2, 1.1 Hz, 1H), 8.64 – 8.61 (m, 1H), 8.29 (d, J 
= 7.2 Hz, 1H), 8.24 (d, J = 8.0 Hz, 1H), 7.71 (td, J = 7.8, 1.8 Hz, 1H), 7.31 (t, J = 7.8 Hz, 
1H), 7.19 (dd, J = 7.6, 1.0 Hz, 1H), 7.17 – 7.16 (m, 1H), 7.09 (ddd, J = 7.4, 4.9, 1.1 Hz, 
1H), 6.91 (ddd, J = 9.2, 6.4, 0.8 Hz, 1H), 6.78 (ddd, J = 8.0, 2.3, 0.8 Hz, 1H), 6.66 – 6.61 
(m, 1H), 3.70 (ddd, J = 46.5, 42.9, 37.3 Hz, 2H). 13C NMR (126 MHz, CDCl3) δ 154.95, 
148.85, 147.17, 138.33, 136.29, 130.95, 130.16, 129.86, 121.98, 121.69, 121.02, 120.37, 
119.99, 118.13, 115.69, 115.10, 113.71. 
2-amino-4-(1-(pyridin-2-yl)imidazo[1,5-a]pyridin-3-yl)phenol (69d): Recrystallization 
(ethanol) afforded compound 69d (68%) as yellow solid. mp 264-267 °C; 1H NMR (500 
MHz, DMSO) δ 9.54 (s, 1H), 8.59 (d, J = 3.6 Hz, 1H), 8.56 (d, J = 9.1 Hz, 1H), 8.39 (d, J 
= 7.1 Hz, 1H), 8.10 (d, J = 8.0 Hz, 1H), 7.80 (t, J = 7.7 Hz, 1H), 7.16 (dd, J = 14.2, 8.7 
Hz, 1H), 7.11 (s, 1H), 7.03 – 6.96 (m, 1H), 6.91 (d, J = 8.0 Hz, 1H), 6.84 (d, J = 8.0 Hz, 
1H), 6.79 (t, J = 6.7 Hz, 1H), 4.79 (s, 2H). 13C NMR (126 MHz, DMSO) δ 155.28, 
149.60, 145.52, 139.29, 137.77, 137.06, 129.66, 129.15, 123.12, 121.89, 121.30, 120.91, 
119.52, 116.94, 114.93, 114.62, 114.30. 
2-methyl-5-(1-(pyridin-2-yl)imidazo[1,5-a]pyridin-3-yl)aniline (69e): 
Recrystallization (ethanol) afforded compound 69e (40%) as orange crystal. mp 165-167 
°C; 1H NMR (500 MHz, CDCl3) δ 8.67 (dt, J = 9.2, 1.2 Hz, 1H), 8.62 (ddd, J = 4.8, 1.8, 




1H), 7.19 (d, J = 7.6 Hz, 1H), 7.14 (d, J = 1.5 Hz, 1H), 7.13 (d, J = 1.6 Hz, 1H), 7.12 (d, 
J = 1.7 Hz, 1H), 7.08 (ddd, J = 7.4, 4.9, 1.1 Hz, 1H), 6.89 (ddd, J = 9.2, 6.4, 0.9 Hz, 1H), 
6.60 (ddd, J = 7.4, 6.5, 1.2 Hz, 1H), 3.84 – 3.67 (m, 2H), 2.24 (s, 3H). 13C NMR (101 
MHz, CDCl3) δ 155.17, 148.96, 145.31, 138.49, 136.18, 130.88, 130.21, 130.03, 128.72, 
123.34, 122.01, 121.69, 120.83, 120.30, 119.93, 118.14, 114.91, 113.55, 17.32. 
4.4 Reduction of Imidazopyridine  
To a 50ml two-neck flask equipped with a magnetic stirrer and condenser at 90oC 
under nitrogen was added IMP (0.5mmol), Pd/C (15 mol%) and ethanol (10ml). After 
running reaction at 90 oC for five min, hydrazine hydrate (7.5mmol) was added drop-
wise. Reaction was monitored via TLC. After completion of reaction the solution was 
filtered. The filtrate was reduced to half volume. If no precipitate was formed on cooling, 
water was added to form precipitate. The precipitate was filtered and dried under UV 
Lamp.  
4-(1-(pyridin-2-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-3-yl)aniline (70a): 
Recrystallization (ethanol/water) afforded compound 70a (84%) as white powder. mp 
232-234 °C; 1H NMR (500 MHz, DMSO) δ 8.50 (ddd, J = 4.9, 1.8, 0.9 Hz, 1H), 7.95 (dt, 
J = 8.1, 1.0 Hz, 1H), 7.73 (ddd, J = 8.0, 7.5, 1.9 Hz, 1H), 7.41 – 7.37 (m, 2H), 7.10 (ddd, 
J = 7.4, 4.9, 1.2 Hz, 1H), 6.67 – 6.64 (m, 2H), 5.38 (s, 2H), 4.03 (t, J = 5.8 Hz, 2H), 3.22 
(t, J = 6.4 Hz, 2H), 1.90 – 1.78 (m, 4H). 13C NMR (126 MHz, DMSO) δ 155.49, 148.95, 
148.63, 145.78, 136.09, 133.33, 129.24, 128.50, 119.80, 119.10, 118.03, 113.38, 44.71, 





Recrystallization (ethanol/water) afforded compound 70b (78%) as white powder. mp 
182-184 °C; 1H NMR (500 MHz, DMSO) δ 8.53 (ddd, J = 4.8, 1.8, 0.9 Hz, 1H), 7.93 (dt, 
J = 8.1, 0.9 Hz, 1H), 7.81 – 7.69 (m, 1H), 7.29 (dd, J = 7.7, 1.4 Hz, 1H), 7.16 – 7.09 (m, 
2H), 6.82 (dd, J = 8.2, 1.0 Hz, 1H), 6.63 (td, J = 7.5, 1.1 Hz, 1H), 5.85 (s, 2H), 3.98 (d, J 
= 5.4 Hz, 2H), 3.24 (t, J = 5.7 Hz, 2H), 1.89 – 1.79 (m, 4H). 13C NMR (126 MHz, 
DMSO) δ 155.12, 148.76, 147.28, 143.50, 136.29, 133.14, 129.32, 129.25, 128.62, 
120.07, 119.10, 115.45, 115.31, 113.19, 44.73, 23.73, 22.78, 19.56. 
3-(1-(pyridin-2-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-3-yl)aniline (70c): 
Recrystallization (ethanol/water) afforded compound 70c (79%) as white powder. mp 
177-179 °C; 1H NMR (500 MHz, DMSO) δ 8.51 (ddd, J = 4.8, 1.8, 0.9 Hz, 1H), 7.95 (dt, 
J = 8.0, 1.0 Hz, 1H), 7.75 (ddd, J = 8.0, 7.5, 1.9 Hz, 1H), 7.18 – 7.07 (m, 2H), 6.98 – 6.94 
(m, 1H), 6.86 – 6.80 (m, 1H), 6.65 – 6.58 (m, 1H), 5.23 (s, 2H), 4.06 (t, J = 5.7 Hz, 2H), 
3.23 (t, J = 6.4 Hz, 2H), 1.91 – 1.76 (m, 4H). 13C NMR (126 MHz, DMSO) δ 155.32, 
148.76, 148.71, 145.48, 136.20, 133.73, 131.23, 129.23, 128.83, 120.03, 119.15, 115.71, 
113.91, 44.94, 23.83, 22.82, 19.54. 
2-amino-4-(1-(pyridin-2-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-3-yl)phenol 
(70d): Recrystallization (ethanol/water) afforded compound 70d (72 %) as white powder. 
mp 262-264 °C; 1H NMR (500 MHz, DMSO) δ 9.31 (s, 1H), 8.50 (ddd, J = 4.9, 1.8, 0.9 
Hz, 1H), 7.93 (dt, J = 8.0, 1.0 Hz, 1H), 7.75 – 7.71 (m, 1H), 7.10 (ddd, J = 7.4, 4.9, 1.2 




4.67 (s, 2H), 4.02 (t, J = 5.7 Hz, 2H), 3.21 (t, J = 6.3 Hz, 2H), 1.88 – 1.78 (m, 4H). 13C 
NMR (126 MHz, DMSO) δ 155.80, 149.14, 146.33, 144.97, 136.97, 136.67, 133.80, 
129.18, 122.52, 120.41, 119.63, 117.38, 115.14, 114.42, 45.31, 24.26, 23.30, 20.03. 
2-methyl-5-(1-(pyridin-2-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-3-yl)aniline 
(70e): Recrystallization (ethanol/water) afforded compound 70e (72 %) as white powder. 
mp 165-166 °C; 1H NMR (500 MHz, DMSO) δ 8.49 (ddd, J = 4.8, 1.8, 0.9 Hz, 1H), 7.93 
(dt, J = 8.1, 1.0 Hz, 1H), 7.76 – 7.70 (m, 1H), 7.11 (ddd, J = 7.4, 4.9, 1.2 Hz, 1H), 7.01 
(d, J = 7.8 Hz, 1H), 6.98 (d, J = 1.7 Hz, 1H), 6.79 (dd, J = 7.6, 1.7 Hz, 1H), 4.94 (s, 2H), 
4.02 (t, J = 5.7 Hz, 2H), 3.25 – 3.16 (m, 2H), 2.09 (s, 3H), 1.88 – 1.75 (m, 4H). 13C NMR 
(126 MHz, DMSO) δ 155.66, 149.16, 146.94, 146.08, 136.72, 134.04, 130.35, 129.56, 
129.28, 122.13, 120.54, 119.71, 116.72, 114.43, 45.35, 24.23, 23.24, 19.98, 17.68. 
2-methoxy-5-(1-(pyridin-2-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-3-yl)aniline 
(70f): Recrystallization (ethanol/water) afforded compound 70f (82 %) as white powder. 
mp 177-178 °C; 1H NMR (500 MHz, DMSO) δ 8.49 (ddd, J = 4.9, 1.8, 0.9 Hz, 1H), 7.92 
(dd, J = 4.9, 4.0 Hz, 1H), 7.77 – 7.69 (m, 1H), 7.11 (ddd, J = 7.4, 4.9, 1.2 Hz, 1H), 7.01 
(d, J = 1.7 Hz, 1H), 6.87 (s, 1H), 6.86 (d, J = 1.8 Hz, 1H), 4.83 (s, 2H), 4.01 (t, J = 5.7 
Hz, 2H), 3.79 (d, J = 11.5 Hz, 3H), 3.18 (dd, J = 12.5, 6.3 Hz, 2H), 1.83 (ddd, J = 16.3, 
9.3, 4.0 Hz, 4H). 13C NMR (126 MHz, DMSO) δ 155.83, 149.34, 147.30, 146.21, 138.10, 
136.91, 134.09, 129.58, 123.90, 120.70, 119.88, 117.30, 114.62, 110.79, 56.02, 45.51, 





Recrystallization (ethanol/water) afforded compound 70g (76%) as a white solid. mp 
150-152 °C; 1H NMR (500 MHz, DMSO) δ 8.52 (ddd, J = 4.8, 1.8, 0.9 Hz, 1H), 7.97 (dt, 
J = 8.0, 1.1 Hz, 1H), 7.76 (t, J = 2.4 Hz, 1H), 7.76 – 7.72 (m, 3H), 7.52 – 7.47 (m, 2H), 
7.46 – 7.41 (m, 1H), 7.13 (ddd, J = 7.4, 4.9, 1.2 Hz, 1H), 4.11 (t, J = 5.7 Hz, 2H), 3.24 (t, 
J = 6.4 Hz, 2H), 1.91 – 1.79 (m, 4H). 13C NMR (126 MHz, DMSO) δ 155.64, 149.19, 
145.18, 136.72, 134.58, 131.18, 130.06, 128.94, 128.74, 120.64, 119.72, 45.32, 24.28, 
23.22, 19.90. 
3-phenyl-1-(pyridin-2-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine (70h); 
Recrystallization (ethanol/water) afforded compound 70h (65%) as a white solid. mp 
150-151 °C; 1H NMR (500 MHz, DMSO) δ 8.55 – 8.48 (m, 1H), 7.97 (d, J = 8.0 Hz, 
1H), 7.80 – 7.71 (m, 3H), 7.52 – 7.47 (m, 2H), 7.43 (ddt, J = 5.5, 4.3, 2.1 Hz, 1H), 7.13 
(ddd, J = 7.4, 4.8, 1.1 Hz, 1H), 4.11 (t, J = 5.7 Hz, 2H), 3.24 (t, J = 6.4 Hz, 2H), 1.91 – 
1.80 (m, 4H). 13C NMR (126 MHz, DMSO) δ 155.62, 149.20, 145.19, 136.73, 134.58, 
131.17, 130.07, 128.95, 128.75, 120.65, 119.72, 45.32, 24.28, 23.22, 19.90. 
3-phenyl-1-(pyridin-2-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine (70i); 
Recrystallization (ethanol/water) afforded compound 70i (73%) as a white solid. mp 151-
152 °C; 1H NMR (500 MHz, DMSO) δ 8.53 (ddd, J = 4.8, 1.8, 0.9 Hz, 1H), 7.98 (dt, J = 
8.0, 1.1 Hz, 1H), 7.79 – 7.70 (m, 3H), 7.54 – 7.47 (m, 2H), 7.47 – 7.41 (m, 1H), 7.14 




1.81 (m, 4H). 13C NMR (126 MHz, DMSO) δ 155.18, 148.73, 144.70, 136.25, 134.11, 
130.72, 129.59, 128.47, 128.27, 120.16, 119.24, 44.85, 23.82, 22.76, 19.43. 
3-phenyl-1-(pyridin-2-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine (70j); 
Recrystallization (ethanol/water) afforded compound 70j (84%) as a white solid. mp 149-
151 °C; 1H NMR (500 MHz, DMSO) δ 8.52 (ddd, J = 4.8, 1.8, 0.9 Hz), 7.98 (dt, J = 7.9, 
0.9 Hz), 7.77 (d, J = 1.8 Hz), 7.74 (ddd, J = 5.6, 3.8, 1.4 Hz), 7.53 – 7.46 (m), 7.46 – 7.40 
(m), 7.13 (ddd, J = 7.3, 4.8, 1.1 Hz), 4.11 (t, J = 5.7 Hz), 3.24 (t, J = 6.3 Hz), 1.86 (ddd, J 
= 14.9, 11.8, 7.7 Hz). 13C NMR (126 MHz, DMSO) δ 155.36, 149.20, 145.31, 136.86, 
134.47, 130.90, 130.10, 129.00, 128.87, 128.77, 120.79, 119.83, 45.32, 24.18, 23.13, 
19.82. 
3-phenyl-1-(pyridin-2-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine (70k); 
Recrystallization (ethanol/water) afforded compound 70k (46%) as a white solid. mp 
149-150 °C; 1H NMR (500 MHz, DMSO) δ 8.53 (ddd, J = 4.8, 1.8, 0.9 Hz, 1H), 7.98 (dt, 
J = 8.0, 1.0 Hz, 1H), 7.79 – 7.72 (m, 3H), 7.50 (ddt, J = 14.7, 9.7, 4.7 Hz, 2H), 7.47 – 
7.41 (m, 1H), 7.14 (ddd, J = 7.4, 4.9, 1.2 Hz, 1H), 4.11 (t, J = 5.7 Hz, 2H), 3.25 (t, J = 6.4 
Hz, 2H), 1.92 – 1.80 (m, 4H). 13C NMR (126 MHz, DMSO) δ 155.19, 148.73, 144.71, 
136.25, 134.12, 130.73, 129.60, 128.48, 128.28, 120.17, 119.25, 44.86, 23.82, 22.76, 
19.44. 
3-(4-fluorophenyl)-1-(pyridin-2-yl)imidazo[1,5-a]pyridine (70l); Recrystallization 
(ethanol/water) afforded compound 70l (66%) as a white solid. mp 165-166 °C; 1H NMR 




7.71 – 7.62 (m, 3H), 7.14 (ddd, J = 10.7, 5.9, 2.5 Hz, 2H), 7.05 (ddd, J = 7.4, 4.9, 1.2 Hz, 
1H), 4.03 (t, J = 5.7 Hz, 2H), 3.36 (t, J = 6.3 Hz, 2H), 1.97 – 1.89 (m, 4H). 13C NMR 
(126 MHz, CDCl3) δ 163.85, 161.88, 155.23, 148.77, 144.75, 136.09, 135.08, 130.65, 
130.59, 129.44, 127.18, 127.15, 120.25, 120.10, 115.66, 115.49, 45.24, 23.83, 23.32, 
20.18.19F NMR (471 MHz, CDCl3) δ -112.72 – -112.81 (m). 
1-(pyridin-2-yl)-3-(p-tolyl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine (70m); 
Recrystallization (ethanol/water) afforded compound 70m (81%) as a white solid. mp 
165-167 °C; 1H NMR (500 MHz, DMSO) δ 8.52 (ddd, J = 4.9, 1.7, 0.8 Hz, 1H), 7.97 (dt, 
J = 8.2, 1.0 Hz, 1H), 7.78 – 7.72 (m, 1H), 7.65 – 7.59 (m, 2H), 7.30 (d, J = 7.9 Hz, 2H), 
7.13 (ddd, J = 7.4, 4.9, 1.2 Hz, 1H), 4.09 (t, J = 5.7 Hz, 2H), 3.24 (t, J = 6.4 Hz, 2H), 2.37 
(s, 3H), 1.92 – 1.78 (m, 4H). 13C NMR (126 MHz, DMSO) δ 155.24, 148.71, 144.78, 
137.71, 136.22, 133.95, 129.39, 129.03, 128.19, 127.94, 120.10, 119.22, 44.81, 23.83, 
22.78, 20.87, 19.46. 
3-(4-(methylthio)phenyl)-1-(pyridin-2-yl)imidazo[1,5-a]pyridine (70n); Reaction did 
not proceed. Recrystallization (ethanol/water) afforded compound 70n yellow solid. mp 
145-146 °C; 1H NMR (500 MHz, CDCl3) δ 8.70 (dt, J = 9.2, 1.2 Hz, 1H), 8.63 (ddd, J = 
4.8, 1.8, 0.9 Hz, 1H), 8.23 (t, J = 7.4 Hz, 2H), 7.76 (d, J = 8.5 Hz, 2H), 7.74 – 7.69 (m, 
1H), 7.41 (d, J = 8.5 Hz, 2H), 7.10 (ddd, J = 7.4, 4.9, 1.2 Hz, 1H), 6.92 (ddd, J = 9.2, 6.4, 
0.9 Hz, 1H), 6.65 (ddd, J = 7.4, 6.5, 1.2 Hz, 1H), 2.55 (s, 3H). 13C NMR (126 MHz, 
CDCl3) δ 154.93, 148.95, 139.88, 137.72, 136.34, 130.52, 130.25, 128.65, 126.68, 





Recrystallization (ethanol/water) afforded compound 70o (76%) as a white solid. mp 
154-155 °C; 1H NMR (500 MHz, CDCl3) δ 8.55 (ddd, J = 4.8, 1.7, 0.8 Hz, 1H), 8.07 (d, J 
= 8.0 Hz, 1H), 7.65 (tt, J = 9.3, 4.7 Hz, 1H), 7.63 – 7.56 (d, 2H), 7.04 (ddd, J = 7.4, 4.9, 
1.1 Hz, 1H), 6.98 – 6.95 (d, 2H), 4.08 (q, J = 7.0 Hz, 2H), 4.03 (t, J = 5.6 Hz, 2H), 3.36 
(t, J = 6.2 Hz, 2H), 1.97 – 1.88 (m, 4H), 1.44 (t, J = 7.0 Hz, 3H). 13C NMR (126 MHz, 
CDCl3) δ 159.18, 155.45, 148.69, 145.70, 136.01, 134.75, 130.09, 129.06, 123.37, 
120.11, 120.04, 114.47, 63.54, 45.18, 23.86, 23.37, 20.26, 14.80. 
N-(4-(1-(pyridin-2-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-3-
yl)phenyl)acetamide (70p); Recrystallization (ethanol/water) afforded 
compound 70p (72%) as a white solid. mp 149-152 °C; 1H NMR (500 MHz, DMSO) δ 
9.94 (s, 1H), 8.53 – 8.50 (m, 1H), 8.01 – 7.98 (m, 1H), 7.81 (dd, J = 4.1, 1.9 Hz, 1H), 
7.74 – 7.67 (m, 3H), 7.61 (d, J = 8.5 Hz, 2H), 7.10 – 7.04 (m, 1H), 4.09 (t, J = 5.5 Hz, 
2H), 3.31 (t, J = 6.2 Hz, 2H), 2.14 (s, 3H), 1.99 – 1.89 (m, 4H). 13C NMR (126 MHz, 
DMSO) δ 169.29, 155.30, 148.75, 145.36, 139.51, 136.13, 134.53, 129.49, 129.01, 
125.66, 120.19, 119.90, 119.41, 45.30, 24.33, 23.91, 23.27, 20.06. 
4.5 Cell Lines Growth 
Prostate cancer cell lines DU145 and PC3were obtained from American Type 
Culture Collections (ATCC, Rockville, MD). DU145 (prostate carcinoma) and PC3 
(prostate adenocarcinoma) are androgen-independent cell lines derived from brain and 




regular culture medium, i.e., in Eagle’s minimum essential medium (MEM) 
supplemented with 5% fetal bovine serum (FBS) 2 μl pipermycin and 2 μl cipromycin 
(91). The Cells were trypsinized to detach from the flask and washed with media. The 
cells were centrifuged at 10000 rpm for 3 min to form pellet. The trypsin and media 
solutions were aspirated from the cell pellet. The cells were re-suspended in media 
supplemented with FBS. The cells were counted via Nexcelom cellometer Auto T4 cell 
counter.  
4.6 Anti-Proliferative Assay 
The colorimetric MTS assay was used to determine the cytotoxicity of IMP and 
rIMP on PC3 and DU145 PCa cells. The trypsinized cells were plated in the 96-well 
plates at a density of 3x104 cell/well and maintained with 5%FBS. The cells were 
incubated for 24 hrs. The cells were treated at various concentrations (1, 10 and 100 μM) 
of IMP and rIMP in the presence of 1% FBS for 72 hrs. The medium was then removed 
and fresh medium containing 20 μl of CellTiter 96® AQueous One Solution Reagent was 
pipetted into each well of the 96-well assay plate. The plate was incubated at 37 oC for 1-
4 hrs in a humidified 5% CO2 atmosphere. The absorbance was recorded at 490 nm using 
a 96-well plate reader. The absorbance values were normalized to the treatment free 







The synthesis of tetrahydroimidazo[1,5-a]pyridine (rIMP) through the transfer 
hydrogenation of imidazo[1,5-a]pyridine (IMP) was successful. The simple two-step 
procedure for the synthesis of rIMP is an extremely viable and efficient method. The 
first-step of the procedure requires the synthesis of IMP and its subsequent 
hydrogenation. The reaction between di-2-pyridil ketone, substituted benzaldehyde, 
ammonium acetate in hot acetic acid under N2 was a viable methodology for the synthesis 
of IMP. The use of reaction conditions of 1:2:5 ratio of di-2-pyridil ketone, substituted 
benzaldehyde and ammonium acetate resulted in good yield of IMP.  
The transfer hydrogenation of IMP using recyclable and inexpensive Pd/C 
catalyst, hydrazine hydrate in ethanol under N2 was shown to be viable and efficient. The 
need of expensive catalyst, pressurized controlled gas and its elaborate equipment were 
not necessary for synthesis of rIMP.  
The reaction conditions for the nitro-based IMP were optimized as to give singly- 
and doubly-reduced products, amine-IMP and amine-rIMP, respectively. Optimization of 
reaction conditions in the synthesis of amine-IMP led to the discovery of 1:3 mol%:3 eq 
ratio of IMP, Pd/C and hydrazine hydrate to obtain high yields. An optimal condition 




regional position of the nitro group in para-position resulted in a high yield compared to 
nitro in ortho- and para-positions. The optimized reaction condition for the synthesis of 
amine-rIMP revealed was 1:15 mol%:15 eq ratio of IMP, Pd/C and hydrazine hydrate 
that lead to high yields. In addition, an optimal temperature of 90 oC was established. The 
presence of hydroxy, alkyl and methoxy groups was unaffected by these reaction 
conditions. The optimized condition for the synthesis of amine-rIMP was used on other 
functionalized IMP with varying results. Hydrogenolysis was observed for halogenated 
bromine- and chlorine-IMP to give non-functionalized rIMP. The halogenated fluorine 
moiety was not affected by the reaction condition and resulted in fluorine-rIMP. The 
nitrile (-CN) group was reduced completely to a methyl (-CH3) group. Whereas the 
ethoxy (-OEt) and acetamide (-NHAc) groups were unaffected. The thiomethyl (-SMe) 
group was found to be poisonous to the catalyst and did not undergo hydrogenation.  
The anti-proliferative assay on PC3 and DU145 showed evidence that the rIMP is 
more potent than IMP at inhibiting growth of PC3 cells, and the IMP more potent at 
inhibiting growth of DU145 cells. Of the various treatments amine-rIMP was more potent 
at inhibiting PC3 cells than Me-rIMP, amine-IMP and OH-IMP. Amine at the ortho-
position was the most potent compared to meta- and para-positions. The cell growth of 






General Aspects and Characterization Data of Compounds 
All the reactions were carried out in nitrogen atmosphere. All the chemicals were 
used as received. Ten percent of palladium on activated carbon from Aldrich was used as 
the catalyst. Melting points were obtained in open capillary tubes with Barnstead 
Electrothermal Mel-Temp 1201D melting point apparatus and are uncorrected. 1H NMR 
(500 MHz), and 13C NMR (126 MHz) spectra were recorded with TMS as an internal 
standard, and 19F NMR (471 MHz) spectra were recorded with 4-fluorobenzaldehyde as a 
reference on Bruker Ultrashield 500 plus. Deuterated solvents DMSO-d6 and CDCl3 were 
used for NMR. Infrared (IR) Spectra were run on either Impart FT-IR spectrometer in 
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